[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 106
1. Navarrete Isidoro O, Abad Fernández A, López Vime R, Jara Chinarro B, Juretschke Moragues MA: [Pulmonary metastasis of Basal cell carcinoma of the skin]. Arch Bronconeumol; 2005 Mar;41(3):169-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastasis of Basal cell carcinoma of the skin].
  • [Transliterated title] Metástasis pulmonares de un carcinoma basocelular cutáneo.
  • Basal cell carcinoma of the skin is a common neoplasm usually considered benign.
  • We report the case of a 41-year old man diagnosed with lung metastasis secondary to base cell carcinoma.
  • Given that the development of metastasis is associated with short survival and the therapeutic arsenal is scarce, we emphasize the importance of long-term follow up of such patients.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Lung Neoplasms / secondary. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15766469.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Ormerod A, Rajpara S, Craig F: Basal cell carcinoma. BMJ Clin Evid; 2010;2010
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma.
  • INTRODUCTION: Basal cell carcinoma (BCC) is the most common form of skin cancer, predominantly affecting the head and neck, and can be diagnosed clinically in most cases.
  • Metastasis of BCC is rare, but localised tissue invasion and destruction can lead to morbidity.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions on treatment response/recurrence (within 1 year of therapy) in people with basal cell carcinoma?
  • What are the effects of interventions on long-term recurrence (a minimum of 2 years after treatment) in people with basal cell carcinoma?
  • [MeSH-major] Carcinoma, Basal Cell. Neoplasm Recurrence, Local
  • [MeSH-minor] Humans. Mohs Surgery. Photochemotherapy. Skin Neoplasms / drug therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Australas J Dermatol. 2000 Feb;41(1):19-30 [10715896.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9 [1869642.001]
  • [Cites] J Am Acad Dermatol. 1992 Nov;27(5 Pt 1):723-8 [1430394.001]
  • [Cites] Aust J Public Health. 1994 Jun;18(2):218-21 [7948343.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):547-53 [18693158.001]
  • [Cites] Dermatol Surg. 2000 Apr;26(4):338-40 [10759821.001]
  • [Cites] Photochem Photobiol. 2000 Jun;71(6):724-9 [10857368.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Dermatol Surg. 2003 Jun;29(6):566-71 [12786697.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):26-32 [14732656.001]
  • [Cites] J Am Acad Dermatol. 1983 Sep;9(3):383-8 [6630599.001]
  • [Cites] J Am Acad Dermatol. 1985 Mar;12(3):522-5 [3989011.001]
  • [Cites] J Dermatol Surg Oncol. 1986 Aug;12(8):860-5 [3734238.001]
  • [Cites] Int J Epidemiol. 1986 Dec;15(4):502-6 [3818157.001]
  • [Cites] J R Coll Physicians Lond. 1987 Apr;21(2):91-6 [3585837.001]
  • [Cites] J Am Acad Dermatol. 1990 Mar;22(3):413-7 [2312827.001]
  • [Cites] Arch Dermatol. 1997 May;133(5):593-6 [9158412.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):144-8 [9754642.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1462-9 [15606733.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):445-51 [16112351.001]
  • [Cites] Dermatol Surg. 2006 Jan;32(1):63-9 [16393600.001]
  • [Cites] J Drugs Dermatol. 2006 Jul-Aug;5(7):642-5 [16865869.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(4):864-70 [18717680.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 Nov;22(11):1302-11 [18624836.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1149-56 [19010733.001]
  • [Cites] Dermatol Surg. 2009 Jan;35(1):24-9 [19018814.001]
  • [Cites] J Invest Dermatol. 2006 Dec;126(12):2679-86 [16841035.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):579-87 [17451581.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1131-6 [17875873.001]
  • [Cites] J Dermatolog Treat. 2008;19(2):111-7 [17917935.001]
  • [Cites] J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1114-8 [2273111.001]
  • (PMID = 21718567.001).
  • [ISSN] 1752-8526
  • [Journal-full-title] BMJ clinical evidence
  • [ISO-abbreviation] BMJ Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2907592
  •  go-up   go-down


3. Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, Christ H, Rapidis AD, Kokkalis G: Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. Anticancer Res; 2009 Jul;29(7):2655-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature.
  • BACKGROUND: Giant basal cell carcinoma (GBCC) is an aggressive malignant neoplasm.
  • The presence of metastasis at the time of presentation represents the most significant adverse prognostic factor.
  • Local recurrence or metastasis develops in 38.3% of patients despite optimal therapy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596942.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 54
  •  go-up   go-down


Advertisement
4. Bariani RL, Nahas FX, Barbosa MV, Farah AB, Ferreira LM: Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population. Acta Cir Bras; 2006 Mar-Apr;21(2):66-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population.
  • PURPOSE: To describe the epidemiological profile of basal cell carcinoma patients at a private hospital in São Paulo and to evaluate the treatment adopted.
  • METHODS: A prospective study of 202 patients, on which 253 lesions were diagnosed for histopathological exam as basal cell carcinoma within the period of January 2001 to September 2003, in the Plastic Surgery Residency Program at the Hospital Jaraguá.
  • RESULTS: The incidence of basal cell carcinoma was 126 cases per 100,000 patients in a period of 32 months (36 cases per 100,000 patients/year).
  • Actinic keratosis and a history of skin cancer were reported in 43.6% and in 25% of the cases, respectively.
  • There were no cases with metastasis or fatal outcome.
  • CONCLUSIONS: The factors related to the development of basal cell cancer which were significantly present in the population surveyed were: older age, white individuals, phototypes I and II, presence of actinic keratosis, previous history of non-melanoma skin cancer and exposure to ultra-violet rays both in recreational and in occupational form.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583057.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


5. Handjani F, Shahbaz S, Sari-Aslani F, Aghaei S, Ali-Zadeh AA: A giant polypoid basal cell carcinoma of the lower extremity. Arch Iran Med; 2010 Mar;13(2):153-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A giant polypoid basal cell carcinoma of the lower extremity.
  • Less than 1% of basal cell carcinomas are giant basal cell carcinomas.
  • Giant basal cell carcinomas are rare.
  • Giant basal cell carcinomas of 10 cm or greater are associated with a high rate of metastasis.
  • We report a case of giant basal cell carcinoma of the leg which is not associated with neglect and no signs of metastasis, despite being more than 10 cm in diameter.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Giant Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Leg. Male. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187672.001).
  • [ISSN] 1735-3947
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


6. O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M: Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Mol Cancer; 2006;5:74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays.
  • BACKGROUND: Skin cancer accounts for 1/3 of all newly diagnosed cancer.
  • Although seldom fatal, basal cell carcinoma (BCC) is associated with severe disfigurement and morbidity.
  • This paper, reporting the first whole genome expression microarray analysis of skin cancer, aimed to investigate the molecular profile of BCC in comparison to non-cancerous skin biopsies.
  • RNA from BCC and normal skin specimens was analysed using Affymetrix whole genome microarrays.
  • RESULTS: Following normalisation, specimens clustered into groups of BCC specimens and of normal skin specimens.
  • Of the 54,675 gene transcripts/variants analysed, 3,921 were differentially expressed between BCC and normal skin specimens.
  • CONCLUSION: Functional gene sets differentially expressed include those involved in transcription, proliferation, cell motility, apoptosis and metabolism.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Gene Expression Profiling. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10311-5 [1332044.001]
  • [Cites] Am J Dermatopathol. 1994 Feb;16(1):60-5 [7512800.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):495-506 [8034748.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3495-9 [7627953.001]
  • [Cites] Br J Dermatol. 1995 Nov;133(5):737-41 [8555026.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1534-41 [8612576.001]
  • [Cites] Br J Dermatol. 1996 Mar;134(3):465-8 [8731670.001]
  • [Cites] EMBO J. 1998 May 1;17(9):2526-33 [9564035.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):215-22 [9815976.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):583-9 [10433950.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9628-32 [10449744.001]
  • [Cites] Pathol Int. 1999 Aug;49(8):687-94 [10504535.001]
  • [Cites] J Cutan Pathol. 2005 Feb;32(2):131-6 [15606671.001]
  • [Cites] Am J Dermatopathol. 2004 Dec;26(6):463-71 [15618927.001]
  • [Cites] Biochem J. 2005 Jan 15;385(Pt 2):469-77 [15367102.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):104-13 [15642389.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):942-9 [15645429.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):853-8 [15868919.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):181-92 [15978322.001]
  • [Cites] J Dermatol Sci. 2005 Jul;39(1):39-51 [15978418.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):237-50 [15986134.001]
  • [Cites] Gene. 2005 Oct 10;359:119-26 [16102918.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Tumour Biol. 2006;27(1):8-16 [16340245.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jan;130(1):45-51 [16390237.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):29-33 [16397211.001]
  • [Cites] J Cutan Pathol. 2006 Feb;33(2):123-8 [16420307.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]
  • [Cites] Cancer Lett. 2006 Jun 8;237(1):22-32 [16023783.001]
  • [Cites] Arch Gerontol Geriatr. 2006 Jul-Aug;43(1):117-26 [16280180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):262-7 [10618406.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(2):215-30 [10728985.001]
  • [Cites] Arch Dermatol. 2000 Jul;136(7):937-8 [10891006.001]
  • [Cites] J Cell Biol. 2000 Jul 10;150(1):177-91 [10893266.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1741-9 [10898789.001]
  • [Cites] Pac Symp Biocomput. 2000;:455-66 [10902193.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Pathologica. 2001 Jun;93(3):208-12 [11433614.001]
  • [Cites] Gene. 2001 Jul 25;273(1):89-96 [11483364.001]
  • [Cites] Br J Dermatol. 2001 Nov;145(5):771-7 [11736900.001]
  • [Cites] Biochem J. 2002 Feb 1;361(Pt 3):497-503 [11802779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6997-7002 [12011458.001]
  • [Cites] Mol Cell. 2002 Sep;10(3):573-84 [12408825.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):459-65 [12496470.001]
  • [Cites] Toxicol In Vitro. 2003 Feb;17(1):85-92 [12537966.001]
  • [Cites] Arch Dermatol. 2003 May;139(5):643-8 [12756102.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9861-6 [12886015.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1221-4 [12946216.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):309-16 [12949813.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Am J Med Genet A. 2003 Nov 15;123A(1):5-28 [14556242.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Apr;286(4):C745-6 [15001424.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3468-73 [14988505.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Mar;149(2):98-106 [15036884.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7548-55 [15187134.001]
  • [Cites] J Cutan Pathol. 2004 Sep;31(8):544-9 [15268709.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):157-64 [15270885.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:3 [14711376.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5651-8 [15313903.001]
  • [Cites] J Clin Periodontol. 2004 Oct;31(10):890-3 [15367194.001]
  • [Cites] Ital J Surg Sci. 1986;16(1):55-9 [2424864.001]
  • [Cites] Am J Dermatopathol. 1989 Apr;11(2):131-5 [2469342.001]
  • [Cites] J Am Acad Dermatol. 1990 May;22(5 Pt 1):721-6 [1693385.001]
  • (PMID = 17173689.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770933
  •  go-up   go-down


7. Chen CC, Chen CL: Clinical and histopathologic findings of superficial basal cell carcinoma: A comparison with other basal cell carcinoma subtypes. J Chin Med Assoc; 2006 Aug;69(8):364-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and histopathologic findings of superficial basal cell carcinoma: A comparison with other basal cell carcinoma subtypes.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer in white populations.
  • We analyzed the age, gender distribution, site of the lesions, clinical appearance, incidence of metastasis, and the proportion of secondary amyloid deposits.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970272.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


8. Rodriguez C, Barriuso V, Chan LS: Extensive basal cell carcinoma with probable bone metastasis. Cutis; 2007 Jul;80(1):60-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive basal cell carcinoma with probable bone metastasis.
  • Metastasis of basal cell carcinoma (BCC) rarely occurs.
  • Once distant metastasis takes place, survival usually is short and palliative treatment is sought.
  • We present a case report of a patient with an extensive BCC with histologic documentation and probable bone metastasis of BCC.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725067.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


9. Lamon T, Gerard S, Meyer N, Losfeld B, Abellan van Kan G, Balardy L, Vellas B: Exceptional bone metastasis of basal cell carcinoma in Gorlin-Goltz syndrome. Dermatology; 2010;220(1):57-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exceptional bone metastasis of basal cell carcinoma in Gorlin-Goltz syndrome.
  • BACKGROUND: Basal cell carcinoma (BCC), the most prevalent form of cancer worldwide, is a malignant skin neoplasm.
  • It is locally invasive, with an exceptional incidence of reported metastasis.
  • OBSERVATION: We report the exceptional clinical observation of a 54-year-old man presenting bone metastasis from BCC in Gorlin-Goltz syndrome.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / secondary. Focal Dermal Hypoplasia / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] European Continental Ancestry Group. Humans. Male. Middle Aged. Neoplasm Metastasis. Pain / etiology. Receptors, Cell Surface / genetics

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996568.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


10. Rajpara S, Ormerod A: Basal cell carcinoma. BMJ Clin Evid; 2008;2008
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma.
  • INTRODUCTION: Basal cell carcinoma (BCC) is the most common form of skin cancer, predominantly affecting the head and neck, and can be diagnosed clinically in most cases.
  • Metastasis of BCC is rare, but localised tissue invasion and destruction can lead to morbidity.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions on treatment response/recurrence (within 1 year of therapy) in people with basal cell carcinoma?
  • What are the effects of interventions on long-term recurrence (a minimum of 2 years after treatment) in people with basal cell carcinoma?
  • [MeSH-minor] Carcinoma, Basal Cell. Dendritic Spines. United States

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19450318.001).
  • [ISSN] 1752-8526
  • [Journal-full-title] BMJ clinical evidence
  • [ISO-abbreviation] BMJ Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


11. Kunte C, Konz B: [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt; 2007 May;58(5):419-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
  • The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.
  • Micrographic histological evaluation should be employed in difficult locations, for large tumors and when there is increased risk of recurrence or metastasis.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]
  • [Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]
  • (PMID = 17443305.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


12. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972311.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ozgediz D, Smith EB, Zheng J, Otero J, Tabatabai ZL, Corvera CU: Basal cell carcinoma does metastasize. Dermatol Online J; 2008;14(8):5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma does metastasize.
  • Basal cell carcinoma (BCC) rarely metastasizes.
  • Metastasis of the tumor to lymph nodes in the left axilla resulted, but the patient remains free of disease 24 months after wide excision, lymph node dissection, and local radiation therapy to the axilla.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Lymphatic Metastasis. Skin Neoplasms / pathology
  • [MeSH-minor] Axilla. Combined Modality Therapy. Disease Progression. Humans. Lymph Node Excision. Male. Middle Aged. Mohs Surgery. Positron-Emission Tomography. Remission Induction. Skin Ulcer / etiology. Thorax. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061565.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Soleymani AD, Scheinfeld N, Vasil K, Bechtel MA: Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread. J Am Acad Dermatol; 2008 Aug;59(2 Suppl 1):S1-3
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread.
  • Basal cell carcinoma (BCC), the most common human malignancy, metastasizes in 0.0028% to 0.5% of cases, usually to the lymph nodes, lungs, bones, and skin.
  • We describe metastatic basal cell carcinoma to the skin presenting with unilateral upper extremity edema.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / secondary. Edema / etiology. Skin Neoplasms / complications. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Arm. Axilla. Biopsy. Humans. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2009 Apr;60(4):704 [19293022.001]
  • (PMID = 18625368.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lackey PL, Sargent LA, Wong L, Brzezienski M, Kennedy JW: Giant basal cell carcinoma surgical management and reconstructive challenges. Ann Plast Surg; 2007 Mar;58(3):250-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma surgical management and reconstructive challenges.
  • Basal cell carcinoma is exceedingly common, but tumors >5 cm in size or giant basal cell carcinomas (GBCCs) are rare.
  • The 10 large defects were reconstructed with 5 free-tissue transfers, 2 pedicled musculocutaneous flaps, and 3 rotational skin flaps.
  • There has been no evidence of local recurrence or metastasis in a mean follow-up of 29 months.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / surgery. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471127.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Suiqing C, Min Z, Lirong C: Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol; 2005 May;32(5):354-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma.
  • In order to evaluate the possible effects of STAT3 phosphorylation and expression of E-cadherin on metastasis of some human epidermal non-melanoma cutaneous tumors, the expression of phosphorylated STAT3 (p-STAT3) and E-cadherin were analyzed by immunohistochemistry staining in formalin-fixed, paraffin-embedded tissue sections of human cutaneous squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and seborrhoeic keratosis (SK).
  • An immunohistochemistry staining technique was employed to measure the expression of p-STAT3 and E-cadherin protein in 30 cases of cutaneous SCC, 20 cases of BCC, 20 cases of SK, and 20 specimens of normal skin.
  • 1) p-STAT3 protein was abnormally increased in SCC as compared to normal skin and SK (p<0.001).
  • The positive rate of the expression of p-STAT3 correlated well with the depth of tumor invasion and with metastasis (p<0.05), but there was no correlation between the positive rate and tumor size.
  • 3) E-cadherin was strongly expressed on the cell membranes of normal skin and SK, especially on basal cells.
  • E-cadherin was weakly expressed on cell membranes of SCC and BCC (p<0.001), whereas its expression was significantly lower in SCC than in BCC (p<0.05).
  • Abnormal activation of STAT3 may be related to metastasis potential in SCC and the simultaneous detection of p-STAT3 and E-cadherin may contribute to predicating the prognosis in SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Invasiveness / physiopathology. Skin Neoplasms / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Case-Control Studies. Female. Humans. Immunohistochemistry. Keratosis, Seborrheic / metabolism. Keratosis, Seborrheic / pathology. Male. Probability. Prognosis. Reference Values. STAT3 Transcription Factor. Sensitivity and Specificity. Tissue Culture Techniques

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043897.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Trans-Activators
  •  go-up   go-down


17. Ting PT, Kasper R, Arlette JP: Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg; 2005 Jan;9(1):10-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: report of two cases and literature review.
  • BACKGROUND: Metastatic basal cell carcinoma (MBCC) is defined as primary cutaneous basal cell carcinoma (BCC) that spreads to distant sites as histologically similar metastatic deposits of BCC.
  • Metastases often involve regional lymph nodes, lungs, bone, and skin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Facial Neoplasms / pathology. Facial Neoplasms / therapy
  • [MeSH-minor] Fatal Outcome. Female. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Metastasis. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208438.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


18. Ionescu DN, Arida M, Jukic DM: Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation. Arch Pathol Lab Med; 2006 Jan;130(1):45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation.
  • CONTEXT: Metastatic basal cell carcinoma (BCC) is relatively rare and is seldom considered a complication in the routine treatment and follow-up of patients with BCC.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Neoplasm Metastasis / pathology. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390237.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


19. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Sveinsdottir SG, Magnusson V, Lindblom A, Kostulas K, Botella-Estrada R, Soriano V, Juberías P, Grasa M, Saez B, Andres R, Scherer D, Rudnai P, Gurzau E, Koppova K, Kiemeney LA, Jakobsdottir M, Steinberg S, Helgason A, Gretarsdottir S, Tucker MA, Mayordomo JI, Nagore E, Kumar R, Hansson J, Olafsson JH, Gulcher J, Kong A, Thorsteinsdottir U, Stefansson K: ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet; 2008 Jul;40(7):886-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma.
  • Fair color increases risk of cutaneous melanoma (CM) and basal cell carcinoma (BCC).
  • Recent genome-wide association studies have identified variants affecting hair, eye and skin pigmentation in Europeans.
  • [MeSH-major] Agouti Signaling Protein / genetics. Carcinoma, Basal Cell / genetics. Melanoma / genetics. Monophenol Monooxygenase / genetics. Pigmentation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Europe. Eye Color / genetics. Gene Frequency. Genetic Predisposition to Disease. Humans. Membrane Glycoproteins / genetics. Middle Aged. Neoplasm Metastasis. Odds Ratio. Oxidoreductases / genetics. Polymorphism, Single Nucleotide. Receptor, Melanocortin, Type 1 / genetics. Registries


20. Gabillot-Carré M, Weill F, Mamelle G, Kolb F, Boitier F, Petrow P, Ortoli JC, Margulis A, Souteyrand P, Mercier S, Spatz A, Duvillard P, Validire P, Avril MF: Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis. Dermatology; 2006;212(3):221-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is a rare cutaneous neoplasm, with a high rate of local recurrences.
  • In 3 patients, the course of the disease was severe: one of them developed pathologically proven lung metastasis.
  • CONCLUSION: The present study and review of the literature confirm the clinically aggressive evolution of MAC and its rare ability to give rise to metastasis.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Facial Neoplasms / pathology. Lung Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 S. Karger AG, Basel
  • (PMID = 16549917.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Garcia C, Poletti E, Crowson AN: Basosquamous carcinoma. J Am Acad Dermatol; 2009 Jan;60(1):137-43
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma.
  • BACKGROUND: Basosquamous carcinoma is considered an aggressive type of basal cell carcinoma (BCC) with an increased risk of recurrence and metastases.
  • METHODS: This is a narrative review based on a MEDLINE search of articles in English and a manual search of popular dermatology textbooks to define basosquamous carcinoma, its incidence, clinical behavior, and treatment of choice.
  • RESULTS: There are no specific clinical features to distinguish basosquamous carcinoma from other BCC types and the diagnosis is made only after biopsy.
  • There are several histologic definitions of basosquamous carcinoma ranging from a characteristic combination of BCC and squamous cell carcinoma with or without a transition zone, to any BCC with evidence of keratinization.
  • The term "metatypical basal cell carcinoma" is considered a synonym but its use is discouraged for the reasons outlined.
  • The reported incidence of basosquamous carcinoma ranges from 1.2% to 2.7%.
  • The incidence of metastasis is at least 5%.
  • The aggressive biological behavior and clinical course distinguish basosquamous carcinoma from other forms of BCC.
  • CONCLUSION: The terminology surrounding basosquamous carcinoma is confusing and there is a need for more uniform language.
  • Data regarding the incidence, recurrence, and metastasis rates of basosquamous carcinoma are based mostly on retrospective series with a limited number of cases.
  • We conclude that although the incidence of basosquamous carcinoma is unknown, there is a literature precedent suggesting more aggressive biological behavior.
  • We believe that complete surgical excision is the preferred approach, and that basosquamous carcinoma is an ideal candidate lesion for Mohs micrographic surgery.
  • [MeSH-major] Carcinoma, Basosquamous. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for basosquamous carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103364.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


22. King R, Lyons J, Meyers AL, Googe PB, Page RN, Gupta VK: Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases. J Cutan Pathol; 2007 Aug;34(8):629-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases.
  • The juxtaposition of malignant melanoma and basal cell carcinoma (BCC) has been rarely reported in case reports, with most cases describing melanoma in situ and BCC.
  • Immunohistochemical studies delineated the two cell populations.
  • Collision tumors containing invasive melanoma and BCC are rare and this is the first report of a collision tumor with blue nevus-like metastasis.
  • Awareness of this phenomenon and pattern of metastasis, together with the clinical findings will aid in the correct classification of these lesions.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Blue / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640233.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


23. Ghafouri-Fard S, Abbasi A, Moslehi H, Faramarzi N, Taba Taba Vakili S, Mobasheri MB, Modarressi MH: Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features. Br J Dermatol; 2010 Apr;162(4):772-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features.
  • BACKGROUND: Basal cell carcinoma (BCC) is characterized by a low rate of metastasis, slow growth and strong stroma dependency, with significant morbidity and public health burden.
  • Their expression patterns were analysed in 78 BCC and 15 normal skin samples using semiquantitative reverse transcription-polymerase chain reaction.
  • RESULTS: SPATA19, TEX101, ODF1, ODF2 and ODF3 were expressed in 56.6%, 38.2%, 2.6%, 17.4% and 2.6% of BCCs but not in normal skin samples.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Heat-Shock Proteins / genetics. Mitochondrial Proteins / genetics. Seminal Plasma Proteins / genetics. Skin Neoplasms / genetics. Testis / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886887.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Heat-Shock Proteins; 0 / Mitochondrial Proteins; 0 / PASD1 protein, human; 0 / SPATA19 protein, human; 0 / Seminal Plasma Proteins
  •  go-up   go-down


24. Østergaard J, Boberg-Ans J, Prause JU, Heegaard S: Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):615-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva.
  • BACKGROUND: To report the clinical and histopathological characteristics of a patient with a primary basal cell carcinoma (BCC) of the caruncle with seeding of the tumour to the conjunctiva.
  • Clinical examination revealed a pale lobulated tumour without skin involvement.
  • Microscopically, both neoplasms were composed of infiltrative islands of basaloid tumour cells, scattered mitoses and peripheral palisading consistent with the diagnosis of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Conjunctival Neoplasms / secondary. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614536.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Mitcov M, Scrivener Y, Cribier B: [Desmoplastic trichoepithelioma: a clinicopathological study, including a comparison with morpheiform basal cell carcinoma]. Ann Dermatol Venereol; 2009 Jun-Jul;136(6-7):501-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoplastic trichoepithelioma: a clinicopathological study, including a comparison with morpheiform basal cell carcinoma].
  • We carried out a retrospective histopathological study of a large series of cases of DTE in order to better characterise this tumour and compare it with sclerodermiform basal cell carcinoma (BCC), which is in fact the most common as well as the most complex type of differential diagnosis.
  • Diagnosis was confirmed by two different examiners and all microscopic elements were reviewed.
  • The diagnosis was only made by the clinician in four cases; in 38 cases the diagnosis made was BCC.
  • Mean clinical follow-up of 8 years (1 to 23 years) in 29 patients showed absence of relapse or metastasis.
  • A suggested clinical diagnosis is thus possible.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560610.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Dastgheib L, Monabati A, Mohammadian A, Sari-Aslani F, Marzban S, Namazi MR: Proteinase-activated receptor-2 expression in basal and squamous cell carcinomas compared with normal skin. J Cutan Pathol; 2009 Mar;36(3):314-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteinase-activated receptor-2 expression in basal and squamous cell carcinomas compared with normal skin.
  • Proteinase-activated receptor-2 (PAR-2) is a transmembrane G-protein expressed in many normal tissues and overexpressed in several cancer cell lines.
  • It contributes to metastasis, promotes epidermal growth factor receptor proliferation, angiogenesis and tumor progression in many carcinomas.
  • The purpose of this study was to investigate the expression of PAR-2 in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in comparison with that of normal skin.
  • Immunohistochemical (IHC) expression of PAR-2 was examined using paraffin-embedded sections from 30 BCCs, 30 SCCs and also 30 normal sun-exposed skin specimens.
  • PAR-2 was expressed in all specimens of SCC and normal skin.
  • Given the important role of PAR-2 in angiogenesis and metastasis, our finding can explain the far less aggressive behavior of BCC as compared with SCC.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Gene Expression Regulation, Neoplastic. Head and Neck Neoplasms / metabolism. Receptor, PAR-2 / biosynthesis. Skin / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032384.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptor, PAR-2
  •  go-up   go-down


27. Wallis S, Durham-Hall A, Tandon N, Brotherston TM, Shrestha BM: Merkel cell carcinoma. JNMA J Nepal Med Assoc; 2010 Apr-Jun;49(178):151-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine tumour of the skin with high rate of local recurrence and distant metastatic potential leading to poor outcomes.
  • Merkel cells are normally found as innervated clusters of cells around hair follicles in the basal layer of the epidermis and are thought to function as touch receptors.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Lymphatic Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21485603.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Nepal
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Unlü RE, Altun S, Kerem M, Koç MN: Is it really necessary to make wide excisions for basal cell carcinoma treatment? J Craniofac Surg; 2009 Nov;20(6):1989-91
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is it really necessary to make wide excisions for basal cell carcinoma treatment?
  • Basal cell carcinoma (BCC) is the common malignancy at the skin arising from the cells of the basal layer of the epithelium or from the external root sheath of the hair follicle.
  • Metastasis is rare, but it recurs if it is inadequately treated.
  • For preventive recurrence, BCC is often excised with wide skin margins.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery. Surgical Procedures, Operative / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881375.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Mackenzie KA, Simcock JW, Lainchbury JG, Currie MJ, Lynn KL: Myocardial metastasis of cutaneous squamous cell carcinoma in a renal transplant recipient. Transplant Proc; 2009 Dec;41(10):4414-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocardial metastasis of cutaneous squamous cell carcinoma in a renal transplant recipient.
  • Myocardial metastasis from a cutaneous squamous cell carcinoma (SCC) is rare.
  • Herein we have presented a case of metastasis from cutaneous SCC to the myocardium in a renal transplant recipient, which was confirmed by a cardiac fine-needle biopsy.
  • Postmortem examination revealed disseminated metastatic disease involving myocardium, lungs, thyroid, skin, and peritoneum secondary to cutaneous SCC likely related to immunosuppression.
  • He started to develop multiple nonmelanoma skin cancers 4 years later.
  • At least 23 invasive SCCs and 14 basal cell carcinomas were excised.
  • His immunosuppressive regimen consisted of cyclosporine (150 mg), azathioprine (75 mg), and prednisone (10 mg daily), which was not modified despite multiple nonmelanoma skin cancers.
  • The management of renal transplant patients with nonmelanoma skin cancers remains difficult and complex.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Heart Neoplasms / secondary. Kidney Transplantation / pathology. Neoplasm Metastasis / pathology. Postoperative Complications / pathology. Skin Neoplasms / pathology


30. Lorenzini M, Gatti S, Giannitrapani A: Giant basal cell carcinoma of the thoracic wall: a case report and review of the literature. Br J Plast Surg; 2005 Oct;58(7):1007-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the thoracic wall: a case report and review of the literature.
  • Giant basal cell carcinoma is a rare skin tumour with aggressive biological behaviour, and deep invasion and metastasis have been reported.
  • The authors describe a giant basal cell carcinoma involving the anterior chest wall.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thoracic Neoplasms / pathology. Thoracic Wall

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2006;59(7):783-4 [16782583.001]
  • (PMID = 16043154.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


31. Elghissassi I, Mikou A, Inrhaoun H, Ennouhi A, Gamra L, Errihani H: Metastatic basal cell carcinoma to the bone and bone marrow. Int J Dermatol; 2009 May;48(5):481-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma to the bone and bone marrow.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common carcinoma in the community, but the incidence of metastatic events is exceedingly low.
  • The few reported cases most often appear in regional nodes or the lungs, and patients usually exhibit multiple concurrent organs of spread at the time of diagnosis.
  • The bone marrow biopsy revealed metastasis of BCC.
  • CONCLUSION: Metastasis of BCC is a very rare condition that should not be overlooked.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Bone Neoplasms / secondary. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416377.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U: Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother; 2008 Jun;31(5):520-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
  • A phase 1 study was initiated to investigate safety, tolerability, serum cytokine levels, cellular immune responses, and clinical activity of intralesional treatment with PF-3512676 in patients with basal cell carcinoma (BCC) or cutaneous or subcutaneous melanoma metastases.
  • Intralesional treatment of skin tumors with PF-3512676 was safe and well tolerated.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Melanoma / drug therapy. Melanoma / pathology. Neoplasm Metastasis. Oligodeoxyribonucleotides / therapeutic use. Toll-Like Receptor 9 / agonists

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18463532.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunoglobulins; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 0 / Toll-Like Receptor 9; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


33. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA; 2005 Aug 10;294(6):681-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years.
  • CONTEXT: The incidence of nonmelanoma skin cancer is increasing rapidly among elderly persons, but little is known about its incidence in the population younger than 40 years.
  • OBJECTIVES: To estimate the sex- and age-specific incidences of basal cell carcinoma and squamous cell carcinoma in persons younger than 40 years in Olmsted County, Minnesota, and to evaluate change in incidence over time; to describe the clinical presentation, rate of recurrence and metastasis, and histologic characteristics of these tumors in this population-based sample.
  • PARTICIPANTS: Patients younger than 40 years with basal cell carcinoma or squamous cell carcinoma diagnosed between 1976 and 2003.
  • MAIN OUTCOME MEASURES: Incident basal cell carcinomas and squamous cell carcinomas and change in incidence of these tumors over time.
  • RESULTS: During the study period, 451 incident basal cell carcinomas were diagnosed in 417 patients and 70 incident squamous cell carcinomas were diagnosed in 68 patients.
  • Of these tumors, 328 were histologically confirmed basal cell carcinomas and 51 were histologically confirmed squamous cell carcinomas.
  • Overall, the age-adjusted incidence of basal cell carcinoma per 100,000 persons was 25.9 (95% confidence interval [CI], 22.6-29.2) for women and 20.9 (95% CI, 17.8-23.9) for men.
  • The incidence of basal cell carcinoma increased significantly during the study period among women (P<.001) but not men (P = .19).
  • Nodular basal cell carcinoma was the most common histologic subtype; 43.0% of tumors were solely nodular basal cell carcinoma and 11.0% had a mixed composition, including the nodular subtype.
  • The incidence of squamous cell carcinoma was similar in men and women, with an average age- and sex-adjusted incidence per 100 000 persons of 3.9 (95% CI, 3.0-4.8); the incidence of squamous cell carcinoma increased significantly over the study period among both women (P = .01) and men (P = .04).
  • CONCLUSIONS: This population-based study demonstrated an increase in the incidence of nonmelanoma skin cancer among young women and men residing in Olmsted County, Minnesota.
  • There was a disproportionate increase in basal cell carcinoma in young women.
  • This increase may lead to an exponential increase in the overall occurrence of nonmelanoma skin cancers over time as this population ages, which emphasizes the need to focus on skin cancer prevention in young adults.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418458.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):279; author reply 279-81 [16418459.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278-9; author reply 279-81 [16418456.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418457.001]
  • (PMID = 16091570.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kazakov DV, Kutzner H, Mukensnabl P, Michal M: Low-grade adnexal carcinoma of the skin with multidirectional (glandular, trichoblastomatous, spiradenocylindromatous) differentiation. Am J Dermatopathol; 2006 Aug;28(4):341-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade adnexal carcinoma of the skin with multidirectional (glandular, trichoblastomatous, spiradenocylindromatous) differentiation.
  • Ten years after the surgery, there was no evidence of recurrence or metastasis.
  • Rare nodules resembled elements seen in a spiradenoma by containing scattered lymphocytes and globules of hyalinized eosinophilic basal membrane material.
  • Mitotic figures, including abnormal ones, were infrequent, but mild nuclear pleomorphism, nuclear crowding, and individual cell necrosis were easily appreciable in both small basaloid cells and cells with clear cytoplasm.
  • We classified this tumor as a well-differentiated adnexal carcinoma demonstrating combined follicular and apocrine differentiation.
  • [MeSH-major] Adnexal Diseases / pathology. Cell Differentiation. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Shape. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871040.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer; 2009;9:262
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.
  • BACKGROUND: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery.
  • The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).
  • This is the first report of such treatment in patients with advance non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Interferons / administration & dosage. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2357-60 [10875919.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40 [11271459.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):933-7 [12072058.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jun;22(6):719-28 [12162884.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1485-95 [12368221.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):116-20 [14692941.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1105-11 [2108862.001]
  • [Cites] Int Ophthalmol. 1990 Jul;14(4):285-94 [2370130.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(5):321-4 [2115817.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1637-49 [2120392.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9 [1869642.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ann Ophthalmol. 1993 Jan;25(1):11-3 [8427483.001]
  • [Cites] Drug Saf. 1994 Feb;10(2):115-50 [7516663.001]
  • [Cites] J Am Acad Dermatol. 1994 Nov;31(5 Pt 2):916-20 [7962748.001]
  • [Cites] Drugs. 1995 Jul;50(1):48-61 [7588089.001]
  • [Cites] Chin Med Sci J. 2007 Mar;22(1):38-43 [17441316.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1974-8 [17513803.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):889-92 [17638733.001]
  • [Cites] J Immunother. 2008 Jan;31(1):28-33 [18157009.001]
  • [Cites] Acta Pol Pharm. 2008 May-Jun;65(3):345-51 [18646554.001]
  • [Cites] J Immunother. 2008 Sep;31(7):599-606 [18600184.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):205-13 [18849299.001]
  • [Cites] Br J Nurs. 2009 Mar 26-Apr 8;18(6):346, 348-50 [19329898.001]
  • [Cites] Cancer Detect Prev. 1997;21(2):191-5 [9101080.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Dermatol Clin. 1998 Apr;16(2):377-98 [9589211.001]
  • [Cites] Acta Oncol. 1999;38(5):613-7 [10427950.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1849-57 [15547726.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):300-4 [15619125.001]
  • [Cites] Ophthalmology. 2005 Apr;112(4):717-23 [15808267.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2937-46 [15837745.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):217-22 [10605014.001]
  • (PMID = 19643007.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9008-11-1 / Interferons
  • [Other-IDs] NLM/ PMC2724551
  •  go-up   go-down


36. Hassanpour SE, Kalantar-Hormozi A, Motamed S, Moosavizadeh SM, Shahverdiani R: Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients. Ann Plast Surg; 2006 Nov;57(5):509-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common human malignant neoplasm.
  • We compared these 2 groups in 16 different parameters, which included general information (age, sex), disease history (time interval from onset of lesion to the first office visit, number of admissions, total length of hospital stay), tumor specifications (number of primary lesions, invasion depth, histologic subtypes, location), surgical history (number of operations in our center and other hospitals, type of surgical treatment, margins of resection), recurrences, new lesions, and metastasis.
  • Only in group A new lesions and metastasis were found.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Basal Cell / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / radiotherapy. Skin Neoplasms / surgery. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Plast Surg. 2007 May;58(5):589; author reply 589-90 [17452854.001]
  • (PMID = 17060730.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Rees JR, Stukel TA, Perry AE, Zens MS, Spencer SK, Karagas MR: Tea consumption and basal cell and squamous cell skin cancer: results of a case-control study. J Am Acad Dermatol; 2007 May;56(5):781-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tea consumption and basal cell and squamous cell skin cancer: results of a case-control study.
  • BACKGROUND: Tea constituents, including polyphenols, are hypothesized to have chemopreventive properties, and inhibit the induction of skin cancers in animal models.
  • OBJECTIVE: To explore the association between regular tea consumption (>or=1 cup/d for >or=1 month) and the incidence of squamous cell (SCC) and basal cell (BCC) carcinomas.
  • CONCLUSIONS: Our findings support the existence of an inverse association between tea consumption and skin carcinogenesis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Sci. 1999 Dec;52(2 Suppl):111-7 [10630599.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Clin Nutr. 2000 Jun;71(6 Suppl):1698S-702S; discussion 1703S-4S [10837321.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):727-31 [10919744.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3864-9 [11051231.001]
  • [Cites] Arch Dermatol. 2001 Sep;137(9):1162-8 [11559211.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):269-85 [11880204.001]
  • [Cites] Cancer Metastasis Rev. 2002;21(3-4):363-80 [12549772.001]
  • [Cites] Br J Dermatol. 2003 Jul;149(1):115-23 [12890204.001]
  • [Cites] Pharmacoeconomics. 2004;22(2):83-94 [14731050.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1992;55:1-316 [1345607.001]
  • [Cites] Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50 [9703491.001]
  • [Cites] Mutat Res. 1999 Jan;436(1):69-97 [9878691.001]
  • [Cites] Photochem Photobiol. 1999 Feb;69(2):148-53 [10048310.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Apr;220(4):234-8 [10202395.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):472S-478S [10721932.001]
  • (PMID = 17261341.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057494-06; United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / CA57494; United States / NCI NIH HHS / CA / R01 CA057494-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tea
  • [Other-IDs] NLM/ NIHMS22520; NLM/ PMC1955322
  •  go-up   go-down


38. Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ: CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol; 2010 May;176(5):2435-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas.
  • Basal cell carcinoma (BCC) is the most common skin malignancy encountered worldwide.
  • In this study, quantitative RT-PCR revealed that the chemokines CXCL9, 10, 11, and their receptor CXCR3 were significantly upregulated by an average 22.6-fold, 9.2-fold, 26.6-fold, and 4.9-fold, respectively in BCC tissue samples as compared with nonlesional skin epithelium.
  • Exposure of HaCaT cells or primary BCC-derived cells to CXCL11 peptides in vitro significantly increased cell proliferation.
  • In primary BCC-derived cell cultures, addition of CXCL11 progressively selected for K17+/CXCR3+ co-expressing cells over time.
  • The expression of CXCR3 and its ligands in human BCC keratinocytes, the enhancement of keratinocyte cell proliferation by CXCL11, and the homogeneity of K17+ BCC cells in human BCC-isolated cell population supported by CXCR3/CXCL11 signaling all suggest that CXCR3 and its ligands may be important autocrine and/or paracrine signaling mediators in the tumorigenesis of BCC.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1999 May 31;145(5):927-32 [10352011.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):71-6 [10508856.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):596-9 [16522748.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):32-42 [17591951.001]
  • [Cites] Hum Pathol. 2007 Nov;38(11):1676-87 [17707463.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):50-6 [17721996.001]
  • [Cites] J Am Acad Dermatol. 2008 Jan;58(1):158-67 [18158927.001]
  • [Cites] N Engl J Med. 2008 Jan 24;358(4):393-401 [18216361.001]
  • [Cites] J Immunol Methods. 2008 Feb 29;331(1-2):140-6 [18234207.001]
  • [Cites] Am J Dermatopathol. 2008 Jun;30(3):249-55 [18496426.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1187-96 [18375741.001]
  • [Cites] J Invest Dermatol. 2008 Jul;128(7):1797-805 [18200053.001]
  • [Cites] J Neuroimmunol. 2008 Aug 13;199(1-2):35-45 [18538864.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):835-43 [18688030.001]
  • [Cites] Arch Dermatol Res. 2010 Mar;302(2):113-23 [19517126.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):780-9 [10597195.001]
  • [Cites] J Immunol. 2000 Jan 15;164(2):733-8 [10623817.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1224-9 [11122025.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9945-54 [11136732.001]
  • [Cites] J Intern Med. 2001 Aug;250(2):91-104 [11489059.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45098-105 [11571298.001]
  • [Cites] Am J Dermatopathol. 2001 Dec;23(6):501-9 [11801790.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):933-41 [12370271.001]
  • [Cites] Int J Dermatol. 2002 Oct;41(10):652-8 [12390187.001]
  • [Cites] J Histochem Cytochem. 2002 Nov;50(11):1425-34 [12417607.001]
  • [Cites] Leukemia. 2003 Jan;17(1):203-10 [12529679.001]
  • [Cites] J Invest Dermatol. 2003 Jul;121(1):191-7 [12839581.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2451-8 [14633617.001]
  • [Cites] Cancer Lett. 2004 Apr 30;207(2):221-7 [15072832.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4010-7 [15173015.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Cell Biol. 1982 Oct;95(1):285-95 [6183270.001]
  • [Cites] J Invest Dermatol. 1983 Jul;81(1 Suppl):33s-40s [6345690.001]
  • [Cites] Lancet. 1987 Aug 22;2(8556):443-6 [2887739.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Br J Dermatol. 1990 Mar;122(3):399-403 [2322501.001]
  • [Cites] Int J Cancer. 1990 Sep 15;46(3):356-61 [2394501.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] Dermatol Clin. 1991 Oct;9(4):751-5 [1934649.001]
  • [Cites] J Invest Dermatol. 1992 Jan;98(1):45-9 [1370231.001]
  • [Cites] Int J Cancer. 1993 Feb 20;53(4):585-90 [8436431.001]
  • [Cites] Carcinogenesis. 1993 May;14(5):833-9 [8504475.001]
  • [Cites] Acta Derm Venereol. 1993 Aug;73(4):286-92 [7506469.001]
  • [Cites] Oncogene. 1995 Sep 7;11(5):961-9 [7675455.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):501-11 [7577575.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Am J Dermatopathol. 1997 Aug;19(4):341-50 [9261468.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):436-45 [9459648.001]
  • [Cites] J Photochem Photobiol B. 1998 Mar;42(3):167-79 [9595706.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):885-8 [9620294.001]
  • [Cites] Blood. 2000 Jan 15;95(2):627-32 [10627472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3438-43 [10725363.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6234-40 [15528361.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503 [15967008.001]
  • [Cites] Amyloid. 2005 Mar;12(1):41-7 [16076610.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1657-67 [15905207.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L909-18 [16339779.001]
  • [Cites] Br J Dermatol. 2006 May;154(5):910-8 [16634895.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2427-33 [16638848.001]
  • [Cites] Am J Dermatopathol. 2006 Aug;28(4):293-307 [16871032.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):667-77 [16881963.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9509-18 [17018607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14842-7 [17003113.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1489-97 [17082008.001]
  • [Cites] Eur J Immunol. 2007 Feb;37(2):338-50 [17274000.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3396-405 [17409450.001]
  • [Cites] Endocrinology. 2007 May;148(5):2317-25 [17255201.001]
  • [Cites] Int J Exp Pathol. 2000 Jun;81(3):183-9 [10971739.001]
  • [Cites] J Dermatol Sci. 1998 May;17(1):15-23 [9651824.001]
  • [Cites] Int J Cancer. 1998 Nov 23;78(5):587-93 [9808527.001]
  • [Cites] Eur J Immunol. 1998 Nov;28(11):3696-705 [9842912.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2682-6 [10068274.001]
  • [CommentIn] Am J Pathol. 2010 May;176(5):2088-91 [20185576.001]
  • (PMID = 20228225.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MUS-94025
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL11 protein, human; 0 / Chemokine CXCL11; 0 / Ligands; 0 / Receptors, CXCR3
  • [Other-IDs] NLM/ PMC2861108
  •  go-up   go-down


39. McCutcheon B, White K, Kotwall C, Germolic D, Rebolloso Y, Hamann MS, Stiles A: A preliminary study of imiquimod treatment in variants of basal cell carcinoma. Am Surg; 2005 Aug;71(8):662-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary study of imiquimod treatment in variants of basal cell carcinoma.
  • Imiquimod is a topical immune response modifier that has proved efficacious in the treatment of the superficial variant of basal cell carcinoma.
  • The nodular variant of basal cell carcinoma has shown moderate response to imiquimod; other variants have not been tested.
  • The objective of this study is to evaluate the cytokine response of imiquimod in all variants of basal cell carcinoma.
  • Ten patients were selected who had clinically and histologically proven basal cell carcinoma.
  • We concluded that topical 5 per cent imiquimod is an effective treatment of various subtypes of basal cell carcinoma.
  • IL-8, which plays an important role in the development and metastasis of melanoma, may be involved in the mechanism of action of imiquimod on cutaneous malignancies.
  • Larger studies are needed to prove the efficacy of imiquimod on nonsuperficial variants of basal cell carcinoma and cutaneous melanoma metastasis.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Biopsy. Humans. Pilot Projects. Polymerase Chain Reaction. Skin / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217949.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


40. Marasà L, Marasà S, Sciancalepore G: Collagen IV, laminin, fibronectin, vitronectin. Comparative study in basal cell carcinoma. Correlation between basement membrane molecules expression and invasive potential. G Ital Dermatol Venereol; 2008 Jun;143(3):169-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen IV, laminin, fibronectin, vitronectin. Comparative study in basal cell carcinoma. Correlation between basement membrane molecules expression and invasive potential.
  • AIM: Basal cell carcinoma (BCC) is a malignant carcinoma arising by cells of epidermal basal layer and adnexal epithelium.
  • It occurs frequently on sun-exposed regions, and is considered as low potential for metastasis, whereas its local invasion, destruction and recurrence are well known.
  • METHODS: Particularly formalin-fixed, paraffin-embedded tissue from 40 cases of BCC, 20 recurring and 20 not recurring, had been studied, with immunohistochemical techniques to value the distribution of intrinsic and extrinsic components of basal membrane.
  • CONCLUSION: A correlation between basal membrane's break and carcinoma's recurrence has been noticed.
  • [MeSH-major] Basement Membrane / chemistry. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Collagen Type IV / analysis. Fibronectins / analysis. Laminin / analysis. Skin Neoplasms / chemistry. Skin Neoplasms / pathology. Vitronectin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833058.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Fibronectins; 0 / Laminin; 0 / Vitronectin
  •  go-up   go-down


41. Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP: Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope; 2009 Oct;119(10):1994-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck.
  • OBJECTIVES/HYPOTHESIS: To discuss the role of radiotherapy (RT) in the treatment of cutaneous squamous and basal cell carcinomas of the head and neck.
  • CONCLUSIONS: Definitive RT is useful for treating early-stage skin cancers where resection would result in a significant cosmetic and/or functional deficit.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging / classification. Parotid Neoplasms / radiotherapy. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688856.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


42. Arbiser JL: Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma. Cancer Prev Res (Phila); 2010 Jan;3(1):4-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma.
  • This different perspective on Tang et al. (beginning on p. 25 in this issue of the journal) discusses the pivotal role of cyclooxygenase (COX) signaling in the pathogenesis of basal cell carcinoma (BCC).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2007 Aug;21(10):2418-30 [17384145.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):621-33 [16966432.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):1019-28 [18178842.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4267-74 [18594009.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5743-8 [18794083.001]
  • [Cites] Int J Hematol. 2009 Apr;89(3):332-41 [19263190.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1055-61 [19701205.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7224-34 [19738049.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] J Biol Chem. 2009 Nov 20;284(47):32264-71 [19808686.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7654-64 [17699770.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Mol Med. 1998 Jun;4(6):376-83 [10780880.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2239-46 [10786690.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24995-5000 [7559628.001]
  • [Cites] Arch Dermatol. 1996 Oct;132(10):1185-93 [8859029.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Nat Med. 1997 Jul;3(7):788-92 [9212109.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):885-8 [9620294.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5870-4 [15576369.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32 [16203784.001]
  • [CommentOn] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • (PMID = 20051366.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] None / None / / R01 AR047901-06A2; United States / NIAMS NIH HHS / AR / R01 AR050727; United States / NIAMS NIH HHS / AR / R01 AR02030; United States / NIAMS NIH HHS / AR / AR050727-01A1; United States / NIAMS NIH HHS / AR / R01 AR047901-06A2; United States / NIAMS NIH HHS / AR / R01 AR050727-01A1; United States / NIAMS NIH HHS / AR / R01 AR047901
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Cell Surface; 0 / patched receptors
  • [Number-of-references] 23
  • [Other-IDs] NLM/ NIHMS162367; NLM/ PMC3154731
  •  go-up   go-down


43. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM: Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene; 2005 Feb 24;24(9):1491-500
eagle-i research resources. PMID 15674344 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.
  • To examine the role of this zinc finger protein in skin, we expressed the wild-type human allele from inducible and constitutive promoters.
  • When induced in basal keratinocytes, KLF4 rapidly abolished the distinctive properties of basal and parabasal epithelial cells.
  • KLF4 caused a transitory apoptotic response and the skin progressed through phases of hyperplasia and dysplasia.
  • By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26737-40 [11389134.001]
  • [Cites] Cancer Surv. 1998;32:69-113 [10489624.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):778-84 [11698196.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):998-1002 [12060394.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S2-9 [11684435.001]
  • [Cites] Nucleic Acids Res. 1999 Dec 1;27(23):4562-9 [10556311.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37798-806 [10954723.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5867-73 [12384550.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11661-9 [12538588.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):203-5 [12676578.001]
  • [Cites] Development. 2003 Jun;130(12):2767-77 [12736219.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3424-30 [12776194.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):763-70 [14644203.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G23-30 [12919939.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):425-9 [14706334.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]
  • [Cites] Cell. 2004 Jan 23;116(2):235-46 [14744434.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):311-6 [15093538.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2709-19 [15102675.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3815-24 [15173090.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3713-21 [2660980.001]
  • [Cites] Cell Differ Dev. 1990 Apr;30(1):27-34 [2350734.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1147-55 [2161707.001]
  • [Cites] Nature. 1991 Jul 25;352(6333):345-7 [1852210.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Cell. 1993 Sep 10;74(5):813-22 [8374952.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]
  • [Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]
  • [Cites] Cancer Metastasis Rev. 1995 Jun;14(2):113-24 [7554029.001]
  • [Cites] Methods Enzymol. 1995;254:3-20 [8531694.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1621-5 [8658135.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] J Cell Biochem. 1995 Dec;59(4):463-72 [8749716.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31384-90 [8940147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(8):376-83 [9332893.001]
  • [Cites] FEBS Lett. 1997 Dec 15;419(2-3):239-43 [9428642.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10747-54 [9553140.001]
  • [Cites] J Biol Chem. 1998 Jul 10;273(28):17917-25 [9651398.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:111-22 [9893262.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3593-607 [10380881.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]
  • [Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • (PMID = 15674344.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA13148; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P30 CA013148; United States / NCI NIH HHS / CA / R01 CA094030; United States / NCI NIH HHS / CA / R29 CA065686; United States / NCI NIH HHS / CA / CA89019; United States / NCI NIH HHS / CA / R01 CA065686; United States / NCI NIH HHS / CA / CA65686; United States / NCI NIH HHS / CA / CA094030
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Transcription Factors; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS7908; NLM/ PMC1361530
  •  go-up   go-down


44. Ntomouchtsis A, Vahtsevanos K, Patrikidou A, Andreadis C, Tsobanidou C, Antoniades K: Adnexal skin carcinomas of the face. J Craniofac Surg; 2009 Jan;20(1):134-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal skin carcinomas of the face.
  • Skin adnexal neoplasms are rare tumors, and knowledge on their exact histological development and pathogenesis remains fragmented.
  • Their diagnosis and management are frequently troublesome, especially for malignant tumors.
  • Records of patients with histologically confirmed adnexal skin carcinoma managed at a single department during the period 1995 to 2004 were reviewed.
  • Patient biodata, surgical management, and main outcome measures such as locoregional recurrence, distant metastasis, and disease-free and overall survival were recorded.Eleven patients were identified from record analysis.
  • Two patients showed regional metastasis and underwent radical neck dissection.
  • Clinical and histological features, tumor biological behavior, diagnostic difficulties, and recommended management are discussed.In conclusion, adnexal skin tumors should be considered in the differential diagnosis of skin tumors, particularly in view of their more sinister prognosis compared with other nonmelanoma skin tumors.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cohort Studies. Diagnosis, Differential. Disease-Free Survival. Eyelid Neoplasms / surgery. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Nose Neoplasms / surgery. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165010.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Prayaga AK, Loya AC, Gottimukkala SR, Digumarti RR, Maddali LS, Challa S: Cytologic features of primary malignant tumors of skin and adnexae. Acta Cytol; 2008 Nov-Dec;52(6):702-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of primary malignant tumors of skin and adnexae.
  • STUDY DESIGN: Cases of primary malignant tumors of skin and adnexae diagnosed on cytology with histopathology confirmation were retrieved from case records of 1998-2005.
  • RESULTS: Thirty primary malignant tumors of skin and adnexae were analyzed.
  • Melanoma was the most common (n=12), followed by squamous cell carcinoma (SCC) (n=5).
  • There were 3 basal cell carcinomas and 2 cases each of sebaceous carcinoma, Paget's disease of the breast and lymphoma.
  • There were single cases of eccrine carcinoma, malignant trichilemmal tumor, undifferentiated carcinoma and extramedullary myeloid cell tumor.
  • CONCLUSION: Cytodiagnosis of primary malignant tumors of skin and adnexae is possible based on morphology and clinical presentation.
  • [MeSH-major] Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Sebaceous / pathology. Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cytodiagnosis. Humans. Lymphatic Metastasis. Medical Records. Melanoma / pathology. Paget's Disease, Mammary / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068675.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Ullah T, Gurwood AS, Myers MD: Ocular metastasis of cutaneous malignant melanoma. Optometry; 2009 Oct;80(10):572-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular metastasis of cutaneous malignant melanoma.
  • Although cutaneous malignancies include basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma, the majority of cases that result in metastasis, ocular morbidity, and mortality are from sebaceous cell carcinoma and malignant melanoma.
  • Her systemic medical history was significant for the diagnosis of a cutaneous malignant melanoma.
  • Magnetic resonance imaging confirmed the diagnosis of metastatic lesions involving structures of the left orbit ultimately causing reduced visual ability.
  • Although orbital metastasis is considered a terminal finding in these cases, timely diagnosis enables, while limited, the best options for management.
  • [MeSH-major] Melanoma / secondary. Orbital Neoplasms / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801341.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Basile J, Thiers B, Maize J Sr, Lathers DM: Chemokine receptor expression in non-melanoma skin cancer. J Cutan Pathol; 2008 Jul;35(7):623-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor expression in non-melanoma skin cancer.
  • Prior studies have shown that in metastatic melanoma and squamous cell carcinoma of the head and neck upregulation of CXC (alpha) chemokine receptor (CXCR)4 and CC (beta) chemokine receptor (CCR)7 expression is accompanied by downregulation of the chemokine receptor CCR6.
  • However, the expression patterns of CCR6, CCR7 and CXCR4 in non-melanoma skin cancer have yet to be elucidated.
  • METHODS: The expression patterns of CCR6, CCR7 and CXCR4 were determined using an immunohistochemical approach on formalin-fixed, paraffin-embedded normal, pre-cancerous actinic (solar) keratosis, squamous cell carcinoma and basal cell carcinoma tissues.
  • RESULTS: Analysis of chemokine receptor expression showed downregulation of CCR6 and upregulation of CCR7 and CXCR4 in potentially metastatic non-melanoma skin cancer, invasive squamous cell carcinoma, but this pattern did not exist in non-melanoma skin cancer with no metastatic potential, basal cell carcinoma; or actinic keratosis, when compared with normal skin.
  • CONCLUSIONS: Chemokine receptor expression may influence the biological behavior of non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis / metabolism. Receptors, CCR6 / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Analysis of Variance. Biomarkers / metabolism. Down-Regulation. Humans. Immunohistochemistry. Neoplasm Metastasis / physiopathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Skin / metabolism. Skin / pathology. Staining and Labeling. Ultraviolet Rays / adverse effects. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312436.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCR6 protein, human; 0 / CCR7 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR6; 0 / Receptors, CCR7; 0 / Receptors, CXCR4
  •  go-up   go-down


48. Smoller BR: Squamous cell carcinoma: from precursor lesions to high-risk variants. Mod Pathol; 2006 Feb;19 Suppl 2:S88-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma: from precursor lesions to high-risk variants.
  • Cutaneous squamous cell carcinoma is second only to basal cell carcinoma in its incidence within our population.
  • This initial portion of the chapter will focus upon the biologic progression that results in the ultimate development of fully formed squamous cell carcinoma.
  • The latter portion will focus upon the histologic features of squamous cell carcinoma, which may be potential prognostic indicators.
  • While pathologists currently provide clinicians with information about many histologic features that may affect the outcome for patients with melanoma, there is little impetus for similar behavior on the part of pathologists when diagnosing squamous cell carcinomas.
  • This is largely due to the relatively low metastasis rate for these tumors compared with melanomas; however, it may be possible for pathologists to separate out those squamous cell carcinomas with a higher chance for recurrence and metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446718.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Leverkus M, Finner AM, Pokrywka A, Franke I, Gollnick H: Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. Dermatology; 2008;217(3):215-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans.
  • Occasionally, B-cell lymphoma may develop in these patients, and additional neoplastic complications such as basal cell carcinoma or squamous cell carcinoma (SCC) have been reported once each over the past 60 years.
  • [MeSH-major] Acrodermatitis / complications. Borrelia burgdorferi. Carcinoma, Squamous Cell / etiology. Lyme Disease / complications. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Ankle. Chronic Disease. Female. Humans. Neoplasm Metastasis


50. Stepp MA, Pal-Ghosh S, Tadvalkar G, Rajjoub L, Jurjus RA, Gerdes M, Ryscavage A, Cataisson C, Shukla A, Yuspa SH: Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis. Mol Carcinog; 2010 Apr;49(4):363-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis.
  • Syndecan-1 (sdc-1) is a cell surface proteoglycan that mediates the interaction of cells with their matrix, influencing attachment, migration, and response to growth factors.
  • In this study we show that sdc-1 expression is significantly reduced in basal cell, squamous cell, and metastatic human skin cancers compared to normal human skin.
  • In experimental mouse skin tumor induction, compared to wildtype (wt) BALB/c mice, papilloma formation in sdc-1 null mice was reduced by 50% and the percent of papillomas converting to squamous cell carcinoma (SCC) was enhanced. sdc-1 expression on wt mouse papillomas decreased as they converted to SCC.
  • While the proliferative response to phorbol-12-myristate-13-acetate (TPA) did not differ among the genotypes, sdc-1 null mice had an enhanced inflammatory response and retained higher levels of total TGFbeta1 within their skin after TPA treatment. sdc-1 null keratinocytes, transduced in vitro by oncogenic ras(Ha), expressed higher levels of beta4 integrin and had enhanced pSmad2 signaling and reduced senescence when compared to wt ras(Ha)-transduced keratinocytes.
  • When ras(Ha)-transduced cells of both genotypes were grafted onto nude mice, null tumors converted to SCC with higher frequency confirming the skin painting experiments.
  • These data indicate that sdc-1 is important both early in the development of skin tumors and in progression of skin cancers suggesting that reduced expression of sdc-1 could be a useful marker for progression in neoplastic skin lesions.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Pathol. 1999 Sep;26(8):386-90 [10551410.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):293-5 [17936552.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):363-76 [10681390.001]
  • [Cites] Am J Dermatopathol. 2000 Apr;22(2):119-22 [10770430.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):329-32 [10888884.001]
  • [Cites] J Cutan Pathol. 2001 Mar;28(3):135-9 [11168765.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):493-507 [11970960.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4517-31 [12414997.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3783-91 [12902406.001]
  • [Cites] Cancer Biol Ther. 2004 Mar;3(3):276-83 [15034302.001]
  • [Cites] J Cell Physiol. 2008 Jan;214(1):238-49 [17579341.001]
  • [Cites] Nat Protoc. 2008;3(5):799-810 [18451788.001]
  • [Cites] Cell Res. 2009 Jan;19(1):89-102 [19050696.001]
  • [Cites] Wound Repair Regen. 2008 Sep-Oct;16(5):649-60 [19128260.001]
  • [Cites] J Exp Med. 2009 Mar 16;206(3):691-705 [19255147.001]
  • [Cites] Mol Carcinog. 2009 May;48(5):441-53 [18942075.001]
  • [Cites] Nat Cell Biol. 2009 Jun;11(6):777-84 [19448624.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1771-8 [15105299.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6529-35 [2649503.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2966-76 [1533815.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4803-10 [8402665.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):219-28 [8548870.001]
  • [Cites] Cell. 1996 Aug 23;86(4):531-42 [8752208.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):157-61 [9627711.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):307-15 [15549092.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1686-92 [15661932.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2032-41 [15688013.001]
  • [Cites] Science. 2005 Mar 18;307(5716):1773-6 [15774758.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24365-74 [16807246.001]
  • [Cites] Matrix Biol. 2006 Sep;25(7):443-56 [16934444.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1407-16 [16953225.001]
  • [Cites] Mol Biol Cell. 2007 May;18(5):1621-33 [17314405.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):370-80 [17457303.001]
  • [Cites] J Cell Sci. 2007 Aug 15;120(Pt 16):2851-63 [17666434.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):325-30 [10657977.001]
  • (PMID = 20082322.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY013559; United States / Intramural NIH HHS / / ; United States / NEI NIH HHS / EY / EY13559; United States / NEI NIH HHS / EY / R01-EY08512; United States / NEI NIH HHS / EY / R01 EY008512
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Phorbol Esters; 0 / Sdc1 protein, mouse; 0 / Syndecan-1; 20839-06-9 / phorbol-12-myristate
  • [Other-IDs] NLM/ NIHMS469026; NLM/ PMC3653623
  •  go-up   go-down


51. Kapucuoglu N, Basak PY, Bircan S, Sert S, Akkaya VB: Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol Res Pract; 2009;205(2):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical galectin-3 expression in non-melanoma skin cancers.
  • In this study, we evaluated the pattern of expression of galectin-3 in cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), and its correlation with the grade of differentiation in SCC and tumor size.
  • Galectin-3 expression was evaluated by immunohistochemistry in 31 SCCs, 30 BCCs, and 29 non-tumoral skin samples.
  • Galectin-3 expression was higher in normal epidermis than in non-melanoma skin cancers, except for cytoplasmic immunoreactivity in SCC.
  • Cytoplasmic galectin-3 immunoreactivity was significantly higher than nuclear immunoreactivity in non-melanoma skin cancers.
  • There was no correlation between galectin-3 staining and tumor differentiation and lymph node metastasis.
  • Decreased nuclear galectin-3 expression and cytoplasmic immunoreactivity in tumors are important factors in the progression from the normal to the cancerous state in non-melanoma skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Galectin 3 / biosynthesis. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951731.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


52. Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ: Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem; 2008 Jan;56(1):57-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression in normal skin and non-melanoma skin tumors.
  • To understand the role of OPN in human skin cancer, this study is designed to determine whether OPN is expressed in premalignant [solar/actinic keratosis (AK)] and in malignant skin lesions such as squamous cell carcinomas (SCC) and basal cell carcinomas (BCC), as well as in normal skin exposed or not exposed to sunlight.
  • In sunlight-exposed normal skin, OPN is minimally expressed in the basal cell layer, but in contrast to those not exposed to sunlight, OPN is more prominent in the spinous cell layer with increasing intensity toward the granular cell layer.
  • Additionally, OPN is expressed in the hair follicles, sebaceous glands, and sweat glands of normal skin.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1995 Feb;216(2):335-41 [7843278.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):95-100 [7856741.001]
  • [Cites] Arch Dermatol. 1995 Jul;131(7):796-800 [7611795.001]
  • [Cites] Matrix Biol. 1995 Jul;14(7):553-60 [8535605.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]
  • [Cites] Arch Biochem Biophys. 1997 Jul 15;343(2):157-63 [9224725.001]
  • [Cites] Cancer Invest. 1998;16(5):329-44 [9627681.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] J Bone Miner Res. 1998 Jul;13(7):1101-11 [9661074.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):640-6 [9818175.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1250-4 [9824103.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6 [16505010.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):233-46 [16816376.001]
  • [Cites] Arch Dermatol. 2006 Jul;142(7):900-6 [16847207.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7119-27 [16849558.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Jan;10(1):73-6 [17253181.001]
  • [Cites] J Histochem Cytochem. 2007 Apr;55(4):403-9 [17210923.001]
  • [Cites] Pathol Res Pract. 1999;195(11):733-9 [10605692.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):156-63 [10901364.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 19;280(2):460-5 [11162539.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):270-8 [11807984.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1554-8 [11886522.001]
  • [Cites] J Oral Pathol Med. 1999 Mar;28(3):97-101 [10069535.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2271-7 [10473115.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Dent Mater J. 2004 Dec;23(4):650-5 [15688734.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3958-65 [15867397.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):155-66 [15954904.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Exp Cell Res. 2007 Apr 1;313(6):1149-60 [17306792.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2840-50 [17160024.001]
  • [Cites] Bone. 2007 Jun;40(6):1517-28 [17395559.001]
  • [Cites] Diabetes. 2007 Jun;56(6):1662-70 [17360982.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):77-84 [12650610.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Protein Expr Purif. 2003 Aug;30(2):238-45 [12880773.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1749-58 [12919959.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] J Dent Res. 2004 Sep;83(9):664-70 [15329369.001]
  • [Cites] J Surg Res. 2004 Oct;121(2):228-41 [15501463.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7182-6 [3532105.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]
  • [Cites] Genomics. 1989 Aug;5(2):375-7 [2571582.001]
  • [Cites] Anticancer Res. 1989 Sep-Oct;9(5):1291-9 [2686530.001]
  • [Cites] Genomics. 1990 Aug;7(4):491-502 [1974876.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2144-50 [2009532.001]
  • [Cites] Mol Carcinog. 1991;4(3):196-202 [2064725.001]
  • [Cites] J Bone Miner Res. 1992 Jul;7(7):743-54 [1642143.001]
  • [Cites] Mol Biol Cell. 1992 Oct;3(10):1169-80 [1421573.001]
  • [Cites] J Histochem Cytochem. 1994 Mar;42(3):351-61 [8308252.001]
  • [Cites] Endocrinology. 1994 Sep;135(3):863-9 [8070379.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):64-9 [7837792.001]
  • [Cites] Cell Growth Differ. 1997 Oct;8(10):1061-9 [9342184.001]
  • [Cites] J Cell Biochem. 1997 Dec 1;67(3):386-96 [9361193.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1468-78 [9525990.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):23280-5 [8083234.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1210-8 [11961008.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):506-12 [12209742.001]
  • (PMID = 17938278.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090920; United States / NCI NIH HHS / CA / R01 CA90920
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2323122
  •  go-up   go-down


53. Huang CY, Feng CH, Hsiao YC, Chuang SS, Yang JY: Burn scar carcinoma. J Dermatolog Treat; 2010 Nov;21(6):350-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burn scar carcinoma.
  • INTRODUCTION: Since Jean-Nicolas Marjolin reported carcinoma arising in post-traumatic scars in 1828, the term 'Marjolin ulcer' has been applied to malignant changes in burn scars.
  • METHODS: From 1989 to 2008, there were 11 cases noted as burn scar carcinoma in Chang Gung Memorial Hospital.
  • Ten were reported as squamous cell carcinoma (SCC) and the one was verrucous carcinoma.
  • RESULTS: Ten cases underwent an operation initially with wide excision and skin graft or local flap for coverage.
  • One patient received above-knee amputation and adjuvant therapy because recurrent verrucous carcinoma occurred 2 years later.
  • One patient suffered from a new lesion 8 years later and another case had inguinal lymph node metastasis 8 months later.
  • Most scar malignancies are SCC while other cell types are rarer.
  • CONCLUSION: The casual association between burn injuries and a later risk of basal cell carcinoma is questionable.
  • Owing to poor prognosis in advanced scar cancer, the best treatment for scar carcinoma is to prevent the scar from developing repeated ulceration by performing aggressive initial burn wound care: early grafting by surgeons and daily scar care with regular follow-up for patients.
  • [MeSH-major] Burns / complications. Carcinoma, Squamous Cell / surgery. Carcinoma, Verrucous / surgery. Cicatrix / complications. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Extremities. Female. Follow-Up Studies. Humans. Lost to Follow-Up. Male. Middle Aged. Skin Transplantation. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438387.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Ozaki K, Narama I: Merkel cell carcinoma in a cat. J Vet Med Sci; 2009 Aug;71(8):1093-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma in a cat.
  • The proliferating pattern of tumor cells was solid but also trabecular or cord-like in some areas, and lined with small cells resembling mature lymphocytes or basal cells.
  • This is the first report describing now cytokeratin 20 was clearly beneficial for the differential diagnosis of feline Merkel cell carcinoma.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19721365.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Synaptophysin
  •  go-up   go-down


55. Eng TY, Boersma MG, Fuller CD, Goytia V, Jones WE 3rd, Joyner M, Nguyen DD: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol; 2007 Dec;30(6):624-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive review of the treatment of Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is an uncommon but malignant cutaneous neuroendocrine carcinoma with a high incidence of local recurrence, regional lymph node metastases, and subsequent distant metastases.
  • It usually occurs in sun-exposed areas in elderly people, many of whom have a history of other synchronous or metachronous sun-associated skin lesions.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Lymph Node Excision. Lymphatic Metastasis. Prognosis. Sentinel Lymph Node Biopsy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091058.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 206
  •  go-up   go-down


56. Orimoto AM, Neto CF, Pimentel ER, Sanches JA, Sotto MN, Akaishi E, Ruiz IR: High numbers of human skin cancers express MMP2 and several integrin genes. J Cutan Pathol; 2008 Mar;35(3):285-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High numbers of human skin cancers express MMP2 and several integrin genes.
  • BACKGROUND: Basal cell carcinomas (BCC), squamous cell carcinomas (SCC) and cutaneous malignant melanoma (MM) are solid skin cancers derived from different cell types, with different ability to metastasize.
  • Several subtypes of integrins and matrix metalloproteinases (MMP) have been related to malignization and metastasis processes.
  • This work aimed at a quantitative evaluation of skin cancers expressing eight integrins and MMP2 genes.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Gene Expression Regulation, Neoplastic. Integrins / genetics. Matrix Metalloproteinase 2 / genetics. Melanoma / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251742.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Integrins; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


57. Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM: Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. Am J Clin Oncol; 2005 Apr;28(2):205-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare skin neuroendocrine carcinoma frequently occurring in the head and neck area.
  • [MeSH-major] Carcinoma, Merkel Cell / radionuclide imaging. Carcinoma, Merkel Cell / secondary. Lymphatic Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / radionuclide imaging. Carcinoma, Basal Cell / secondary. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Fluorodeoxyglucose F18. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radionuclide imaging. Humans. Male. Middle Aged. Neoplasms, Multiple Primary / radionuclide imaging. Radiopharmaceuticals. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803018.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


58. Adigun IA, Buhari MO, Ayorinde RO: Malignant skin tumor in Blacks: experience in a teaching hospital. West Afr J Med; 2006 Oct-Dec;25(4):276-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant skin tumor in Blacks: experience in a teaching hospital.
  • BACKGROUND: Basal Cell Carcinoma (BCC) is said to be the most common human skin malignancy.
  • METHODS: We retrospectively review 146 patients treated for skin tumors in our tertiary hospital from January 1979 to December 2002.
  • RESULTS: This study showed that Squamous Cell Carcinoma (SCC) is the most common non melanomatous skin tumor in our environment.
  • The study revealed only 8 (5.5%) cases of basal cell carcinoma which is in contrast to what is obtained in the Europe and North America.
  • CONCLUSION: Unlike in the Caucasians, squamous cell carcinoma is the most common non-melanomatous skin tumor in our environment.
  • The tumor is usually more aggressive and more prone to metastasis resulting in severe morbidity and sometimes loss of limb in the affected patient.
  • [MeSH-major] African Continental Ancestry Group. Carcinoma, Basal Cell / ethnology. Carcinoma, Squamous Cell / ethnology. Skin Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17402515.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


59. Cernea CR, Ferraz AR, de Castro IV, Sotto MN, Logullo AF, Bacchi CE, Potenza AS: p53 and skin carcinomas with skull base invasion: a case-control study. Otolaryngol Head Neck Surg; 2006 Mar;134(3):471-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and skin carcinomas with skull base invasion: a case-control study.
  • BACKGROUND: Some skin carcinomas may be very aggressive.
  • In this study, p53 expression was evaluated in basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) with skull base invasion, and was compared to tumors with good outcome.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology. Skull Base Neoplasms / pathology. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Case-Control Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500447.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


60. Anderegg U, Breitschwerdt K, Köhler MJ, Sticherling M, Haustein UF, Simon JC, Saalbach A: MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines. Exp Dermatol; 2005 Sep;14(9):709-18
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines.
  • Tumor-stroma interactions play a decisive role in the growth and metastasis of solid tumors, and involve signalling either by soluble mediators or direct cell-cell interaction.
  • Here, we report the isolation and characterisation of a novel cDNA (MEL4B3), which is induced in cultured dermal fibroblasts exposed to supernatants of melanoma cell lines.
  • In situ hybridisation revealed the expression of MEL4B3 in malignant melanoma increasing with tumor depth; in basal cell carcinoma and in squamous cell carcinoma.
  • MEL4B3 was barely detectable in normal skin or non-malignant melanocytic naevi.
  • Furthermore, MEL4B3 was expressed at high level in the epidermis of psoriatic skin.
  • In vitro, the expression of MEL4B3 was found to be induced by the exposure of human dermal fibroblasts to melanoma cell culture supernatants or to transforming growth factor-beta, interleukin-1 and tumor necrosis factor-alpha.
  • The expression MEL4B3 therefore reflects closely cell activation occurring during tumor growth, metastasis and inflammation.
  • [MeSH-major] Neoplasm Proteins / biosynthesis. RNA, Messenger / metabolism. Skin Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Blotting, Northern. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Cells, Cultured. Culture Media / metabolism. Culture Media / pharmacology. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. DNA, Complementary / metabolism. Fibroblasts / metabolism. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Inflammation. Keratinocytes / metabolism. Microcirculation. Molecular Sequence Data. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Complementary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098131.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Culture Media; 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / DNA, Complementary; 0 / FNDC1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Complementary; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta
  •  go-up   go-down


61. Ming M, He YY: PTEN: new insights into its regulation and function in skin cancer. J Invest Dermatol; 2009 Sep;129(9):2109-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN: new insights into its regulation and function in skin cancer.
  • Skin cancer is the most common cancer in the United States.
  • UV radiation in sunlight is the major environmental factor causing skin cancer development.
  • PTEN is clearly a critical tumor suppressor for skin cancer in humans and in mice.
  • This review summarizes the recent progress in the function of PTEN in the development of skin cancer, including basal-cell carcinoma, squamous-cell carcinoma, and melanoma.
  • The regulation of PTEN by UV radiation is also discussed in association with skin carcinogenesis.
  • Understanding the fundamental mechanisms that lead to the reduction of PTEN function in skin carcinogenesis and the essential association with UV radiation opens up new opportunities for molecular chemoprevention and therapy of skin cancer by targeting PTEN pathways.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2000 Feb;114(2):277-80 [10651986.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):775-85 [16972255.001]
  • [Cites] Hum Mutat. 2000;16(2):109-22 [10923032.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):493-7 [11179477.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2186-9 [11691952.001]
  • [Cites] Nat Cell Biol. 2001 Dec;3(12):1124-8 [11781575.001]
  • [Cites] Oncogene. 2002 Jan 3;21(1):53-64 [11791176.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1650-3 [11886535.001]
  • [Cites] Development. 2002 Sep;129(17):4159-70 [12163417.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):674-81 [12566313.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):318-27 [12569555.001]
  • [Cites] Development. 2003 Apr;130(8):1691-700 [12620992.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3113-22 [12789288.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1725-30 [14747659.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):337-41 [15009714.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7002-10 [15466193.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):743-6 [646396.001]
  • [Cites] Arch Dermatol. 1984 May;120(5):677-8 [6721530.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4756-9 [8062275.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Nat Genet. 1997 Aug;16(4):333-4 [9241266.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13375-8 [9593664.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):152-6 [9598803.001]
  • [Cites] Oncogene. 1998 Jul 2;16(26):3397-402 [9692547.001]
  • [Cites] Cell. 1998 Oct 2;95(1):29-39 [9778245.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] J Dermatol Sci. 1999 Apr;19(3):199-201 [10215192.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2006-11 [15598755.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):273-85 [15986137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1480-5 [16432235.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4505-10 [16537363.001]
  • [Cites] Oncogene. 2006 Jun 22;25(26):3680-8 [16682958.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):999-1005 [17034532.001]
  • [Cites] Cell. 2007 Jan 12;128(1):157-70 [17218262.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):189-98 [17237784.001]
  • [Cites] Hautarzt. 2007 May;58(5):406-11 [17440702.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):578-88 [17295241.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2929-40 [17909629.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):209-13 [18201277.001]
  • [Cites] Adv Exp Med Biol. 2008;624:283-95 [18348464.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5416-30 [18794877.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1693-700 [10793080.001]
  • (PMID = 19340009.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA014599-34; United States / NCI NIH HHS / CA / P30 CA014599-349022; United States / NCRR NIH HHS / RR / UL1 RR024999; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / P30 CA014599-33S1; United States / NCRR NIH HHS / RR / RR024999-01; United States / NCI NIH HHS / CA / P30 CA014599-34; United States / NCI NIH HHS / CA / CA014599-340014; United States / NCI NIH HHS / CA / CA014599-33S1; United States / NCRR NIH HHS / RR / UL1 RR024999-02; United States / NCRR NIH HHS / RR / UL1 RR024999-01; United States / NCI NIH HHS / CA / P30 CA014599-340014; United States / NCI NIH HHS / CA / CA014599-349022
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 45
  • [Other-IDs] NLM/ NIHMS130379; NLM/ PMC2758921
  •  go-up   go-down


62. Jani P, Chetty R, Ghazarian DM: An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature. Am J Dermatopathol; 2008 Apr;30(2):174-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature.
  • We report a case of an extremely rare histologic combination of pilomatrix or pilomatrical carcinoma with admixed melanocytes within the same tumor mass.
  • Pilomatrix carcinoma is a neoplasm of low-grade malignancy that is characterized by a tendency for recurrence but low risk of metastasis.
  • In addition, intermingled with the pilomatrix carcinoma, several easily identified pigmented cells with dendritic processes were present singly and as small aggregates.
  • Pilomatrix carcinoma with melanocytes should be distinguished from the conventional pilomatrixoma with pigmentation, melanocytic matricoma, melanoma, and pigmented basal cell carcinoma with matrical differentiation.
  • Clinicians and pathologists should be aware of the occurrence of pilomatrix carcinoma with melanocytes because of its potential for diagnosis as melanoma.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Hair Diseases / pathology. Melanocytes / pathology. Pilomatrixoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Nose. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360125.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


63. Tran KT, Lamb P, Deng JS: Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J Dermatol Sci; 2005 Oct;40(1):11-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrikines and matricryptins: Implications for cutaneous cancers and skin repair.
  • Dermatologists are faced daily with the need to optimize skin repair and excise cutaneous cancers.
  • The extracellular matrix plays a pivotal role in cellular migration, proliferation, and gene regulation during wound healing and progression of melanoma, basal cell carcinoma, and squamous cell carcinoma.
  • Within the last few years, a new class of ligand, the matrikine or matricryptin, has been characterized as subdomains of various ECM proteins capable of signaling to the cell through receptors, such as growth factor receptors.
  • The EGF-like repeats of tenascin-C and laminin-5 signal to EGFR preferentially to upregulate migration during skin repair and tumor progression.
  • Other matrikines in collagen, elastin, decorin, and laminin-1 can promote chemotaxis, mitogenesis, and metastasis in cancers, such as melanoma.
  • Within the next few years, the nature and function of this emerging class of matrikine ligands will have an impact on dermatology, as these proteins are altered in wound repair and skin diseases.
  • [MeSH-major] Extracellular Matrix Proteins / physiology. Skin Neoplasms / etiology
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Adhesion Molecules / physiology. Collagen / physiology. Humans. Ligands. Molecular Sequence Data. Signal Transduction. Tenascin / physiology. Tissue Engineering. Wound Healing

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15993569.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Extracellular Matrix Proteins; 0 / Ligands; 0 / Tenascin; 0 / kalinin; 9007-34-5 / Collagen
  • [Number-of-references] 50
  •  go-up   go-down


64. Schulz T, Proske S, Hartschuh W, Kurzen H, Paul E, Wünsch PH: High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread. Am J Dermatopathol; 2005 Feb;27(1):9-16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread.
  • The concept was recently forwarded that basal cell carcinoma is as a malignant neoplasm of follicular germinative cells and should be named trichoblastic carcinoma to show its relationship to trichoblastoma.
  • Almost all basal cell carcinomas are low-grade malignant neoplasms and develop metastases only very rarely, and if so, only after very long duration and untreated growth.
  • Only rare basal cell carcinomas arise in trichoblastomas.
  • Up to now there have only been two reports of high-grade trichoblastic carcinoma arising in trichoblastoma, showing systemic metastatic spread and death.
  • We add two further cases of trichoblastic carcinoma with anaplastic nuclei, arising in trichoblastoma.
  • The other one was a trichoblastic carcinoma at the base of a trichoepithelioma on the right thigh of an 87-year-old woman with Brooke-Spiegler syndrome.
  • Our cases emphasize that high-grade trichoblastic carcinoma develops via malignant transformation of trichoblastoma, and is very rare.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Carcinoma, Skin Appendage / secondary. Hair Diseases / pathology. Hair Follicle / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Female. Humans. Immunoenzyme Techniques. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15677970.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


65. Merritt BG, Snow SN, Longley BJ: Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery. Cutis; 2010 May;85(5):254-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery.
  • Desmoplastic trichoepithelioma (DTE), infiltrative/morpheaform basal cell carcinoma (BCC), and microcystic adnexal carcinoma (MAC) are tumors in this category that may be difficult to differentiate, especially when evaluating thin biopsy specimens.
  • An accurate diagnosis has important clinical implications.
  • While DTE is a benign neoplasm with indolent behavior, infiltrative/morpheaform BCC and MAC can be highly aggressive, leading to substantial local destruction and potential metastasis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Skin Appendage / pathology. Mohs Surgery. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-20. Male. Middle Aged. Staining and Labeling

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540416.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20
  •  go-up   go-down


66. Vucetić B, Rogan SA, Hrabac P, Hudorović N, Cupić H, Lukinac L, Ledinsky M, Matejcić A, Lovricević I, Zekan M: Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res; 2008 Jun;18(3):201-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma.
  • In addition, MIA serum levels were studied in two control groups; patients with dysplastic nevi and patients with basal cell carcinoma.
  • [MeSH-major] Extracellular Matrix Proteins / blood. Melanoma / blood. Melanoma / diagnosis. Neoplasm Proteins / blood. Skin Neoplasms / blood. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / pathology. Dysplastic Nevus Syndrome / blood. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Predictive Value of Tests. Prognosis. Reference Values. Sensitivity and Specificity. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477894.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / MIA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


67. Otley CC: Non-Hodgkin lymphoma and skin cancer: A dangerous combination. Australas J Dermatol; 2006 Nov;47(4):231-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma and skin cancer: A dangerous combination.
  • There is a significant association between non-Hodgkin lymphoma, including chronic lymphocytic leukaemia, and both melanoma and non-melanoma skin cancer.
  • This review highlights the existing data on the phenomenon of accelerated skin cancer in patients with non-Hodgkin lymphoma and specifically chronic lymphocytic leukaemia.
  • The outcomes of patients with non-Hodgkin lymphoma (including chronic lymphocytic leukaemia) and non-melanoma skin cancer are worse than in patients without concomitant lymphoreticular malignancy, as shown by increased rates of local recurrence, regional metastasis and death.
  • Pathogenic factors may be common between non-Hodgkin lymphoma and chronic lymphocytic leukaemia and skin cancer.
  • The treatment of skin cancer in patients with non-Hodgkin lymphoma must factor in the worse prognosis and adapt standard therapeutic approaches to minimize the risk of metastasis and death.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / physiopathology. Carcinoma, Basal Cell / therapy. Carcinoma, Merkel Cell / complications. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / physiopathology. Carcinoma, Merkel Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / physiopathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Humans. Melanoma / complications. Melanoma / diagnosis. Melanoma / physiopathology. Melanoma / therapy. Prognosis. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / physiopathology. Sarcoma, Kaposi / therapy. Xanthomatosis / complications. Xanthomatosis / diagnosis. Xanthomatosis / physiopathology. Xanthomatosis / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034463.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 44
  •  go-up   go-down


68. Thurfjell N, Coates PJ, Boldrup L, Lindgren B, Bäcklund B, Uusitalo T, Mahani D, Dabelsteen E, Dahlqvist A, Sjöström B, Roos G, Vojtesek B, Nenutil R, Nylander K: Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol; 2005;62:49-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck.
  • BACKGROUND/AIMS: Squamous cell carcinoma of the head and neck (HNSCC) is the 6th most common malignancy worldwide with a 5-year survival that has not improved over the last 20-25 years.
  • Factors of prognostic significance for this tumour type include the presence of regional lymph node metastasis and amplification of chromosome 3q21-29, where the p63 gene is located.
  • This gene encodes 6 proteins and is crucial for formation of the oral mucosa, teeth, salivary glands and skin.
  • RESULTS/CONCLUSION: Expression of p63 proteins differs between the cell layers in normal oral mucosa, and primary HNSCC has a high expression level of p63 isoforms normally expressed in basal cells.
  • Data suggest that p63 expression in HNSCC influences tumour cell differentiation.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism


69. Serrels B, Serrels A, Mason SM, Baldeschi C, Ashton GH, Canel M, Mackintosh LJ, Doyle B, Green TP, Frame MC, Sansom OJ, Brunton VG: A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. Carcinogenesis; 2009 Feb;30(2):249-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
  • The Src family tyrosine kinases are key modulators of cancer cell invasion and metastasis and a number of Src kinase inhibitors are currently in clinical development for the treatment of solid tumours.
  • We have investigated the role of Src in mouse skin, which is one of the most tractable models of epithelial homoeostasis and tumorigenesis.
  • AZD0530, a selective Src inhibitor, prevented the TPA-induced proliferation of basal keratinocytes both in vivo and in vitro.
  • Moreover, treatment with AZD0530 reduced papilloma formation following the well-established 7,12-dimethylbenz(a)anthracene/TPA skin carcinogenesis protocol but did not inhibit the subsequent proliferation of the papillomas.
  • Furthermore, AZD0530 did not alter the malignant conversion of papillomas to squamous cell carcinoma suggesting a role for Src in early tumour development in the skin carcinogenesis model, rather than at later stages of tumour progression.
  • Src expression and activity were also seen in human actinic keratoses that are hyperproliferative pre-malignant skin lesions, indicating that Src may also play a role in the early stages of human skin tumour development.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Benzodioxoles / therapeutic use. Cell Transformation, Neoplastic / drug effects. Quinazolines / therapeutic use. Skin Neoplasms / prevention & control. src-Family Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Carcinoma, Squamous Cell / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Female. Humans. Keratinocytes / cytology. Keratinocytes / drug effects. Keratosis / metabolism. Male. Mice. Middle Aged. Papilloma / chemically induced. Papilloma / drug therapy. Precancerous Conditions / metabolism. Tetradecanoylphorbol Acetate

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19060248.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0601648; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Benzodioxoles; 0 / Quinazolines; 9KD24QGH76 / saracatinib; EC 2.7.10.2 / src-Family Kinases; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


70. Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T: Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol; 2005 Apr;32(4):257-62
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
  • INTRODUCTION: Imiquimod (Aldara) is an immune response modifier approved for the topical treatment of external genital and perianal warts which can mediate regression of several cutaneous malignancies [basal cell carcinoma (BCC), Bowen's disease, actinic keratosis, and metastasis of malignant melanoma].
  • PATIENTS AND METHODS: In the present study we analyzed the expression of MxA, a protein specifically induced by type I IFNs during topical imiquimod treatment in several patients suffering from different cutaneous malignancies (BCC, cutaneous metastasis of melanoma, and breast cancer), and characterized the inflammatory infiltrate, along with the expression of chemokine receptor CXCR3, by immunohistochemistry.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Interferon Type I / immunology. Lymphocytes / immunology. Membrane Glycoproteins / agonists. Receptors, Cell Surface / agonists. Receptors, Chemokine / immunology. Skin / immunology
  • [MeSH-minor] Breast Neoplasms / immunology. Breast Neoplasms / secondary. Carcinoma, Basal Cell / immunology. Carcinoma, Basal Cell / secondary. Chemotaxis, Leukocyte / drug effects. Chemotaxis, Leukocyte / immunology. Female. Humans. Melanoma / immunology. Melanoma / secondary. Receptors, CXCR3. Signal Transduction. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Toll-Like Receptor 7. Toll-Like Receptors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15769273.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / CXCR3 protein, human; 0 / Interferon Type I; 0 / Membrane Glycoproteins; 0 / Receptors, CXCR3; 0 / Receptors, Cell Surface; 0 / Receptors, Chemokine; 0 / TLR7 protein, human; 0 / Toll-Like Receptor 7; 0 / Toll-Like Receptors; 99011-02-6 / imiquimod
  •  go-up   go-down


71. Lustgarten L, Abadi JR, Sancevic R, Meneses P, Perez Morrel A, Lugo J: Use of a protein-based tissue adhesive as an aid for the surgical reconstruction of advanced and recurrent skin cancer tumors to the head and neck region: a technical report. Surg Neurol; 2007 Jul;68(1):53-9; discussion 59
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a protein-based tissue adhesive as an aid for the surgical reconstruction of advanced and recurrent skin cancer tumors to the head and neck region: a technical report.
  • BACKGROUND: Patients with advanced skin cancer present a unique challenge to neurosurgeons.
  • METHODS: Between January 2000 and June 2004, 11 patients ranging in age from 32 to 87 years presented with advanced skin cancer tumors in the head and neck.
  • Pathology included squamous (7) and basal (3) cell carcinoma and malignant schwannoma (1).
  • The remaining patients are alive, and our follow-up (range, 9-58 months) has revealed no recurrence or distal metastasis.
  • CONCLUSIONS: Advanced skin cancer tumors in the head and neck region are associated with complex and disfiguring surgical procedures with increased morbidity.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Neurosurgical Procedures. Proteins / therapeutic use. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Tissue Adhesives / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / surgery. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Craniotomy. Dura Mater / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neurilemmoma / surgery. Nose / surgery. Orbit / surgery. Postoperative Complications / mortality

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586223.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bio-glue; 0 / Proteins; 0 / Tissue Adhesives
  •  go-up   go-down


72. Plaza JA, Ortega PF, Stockman DL, Suster S: Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. J Cutan Pathol; 2010 Apr;37(4):403-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases.
  • The distinction of metastatic carcinomas to the skin from poorly differentiated primary cutaneous carcinomas and sometimes primary benign adnexal tumors can pose a significant diagnostic challenge.
  • The purpose of this study was to evaluate the role of p63 and podoplanin (D2-40) immunoreactivity for separating primary skin tumors vs. cutaneous metastases of carcinomas from internal organs.
  • The 37 primary cutaneous tumors included 14 cases of benign adnexal tumors, 9 malignant skin adnexal neoplasms, and 14 primary squamous and basal cell carcinomas.
  • We found variable positivity with podoplanin in all primary cutaneous neoplasms including spiradenoma (6/6), hidradenoma (2/4), cylindroma (3/3), desmoplastic trichilemmoma (1/1), poorly differentiated squamous cell carcinoma (4/4), sebaceous carcinoma (1/1), basal cell carcinoma (4/10), trichilemmal carcinoma (2/2), eccrine carcinoma (3/3), microcystic adnexal carcinoma (1/1), adnexal carcinoma NOS (1/1), and porocarcinoma (1/1).
  • Sensitivity, specificity, and positive and negative predictive values of podoplanin and p63 immunoreactivity to separate primary skin neoplasms from metastatic carcinomas were 78.4, 100.0, 100.0 and 84.0% for podoplanin, respectively, and 100.0, 100.0, 100.0 and 100.0% for p63, respectively.
  • The differences in p63 and podoplanin immunohistochemical expression between primary skin tumors and metastatic carcinomas to the skin were statistically significant (p < 0, 0001).
  • The results of our study suggest that the combined expression of p63 and podoplanin are a useful adjunct for the diagnosis of skin tumors in the clinical setting of a questionable metastasis and may be relatively specific for distinguishing primary skin tumors from metastatic carcinomas to the skin.
  • [MeSH-major] Adenocarcinoma / metabolism. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377670.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / PDPN protein, human
  •  go-up   go-down


73. Reichrath J, Nürnberg B: Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs). Adv Exp Med Biol; 2008;624:203-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs).
  • It is well known that skin cancer, especially SCC, in this population has higher incidence rates, behaves more aggressively and has higher rates of metastasis.
  • OTRs who have been treated for many years with immunosuppressive medication are at the highest risk for developing malignant skin tumors.
  • A full-body skin exam at least once a year and more frequently if skin cancer or precancerous cutaneous lesions develop is recommended.
  • Clinicians should not hesitate to biopsy or to surgically excise any suspicious skin lesion.
  • Protection against solar and artificial UV-radiation and monthly self-examinations are good ways to prevent and to recognize any new suspicious skin lesions.
  • A sunscreen with a sun protection factor (SPF)-8 reduces the skin's production of vitamin D by 95%.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Carcinoma, Squamous Cell / immunology. Skin Neoplasms / immunology. Transplants. Ultraviolet Rays / adverse effects. Vitamin D / immunology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348458.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vitamins; 1406-16-2 / Vitamin D
  • [Number-of-references] 79
  •  go-up   go-down


74. Satter EK, Derienzo DP: Synchronous onset of multiple cutaneous neuroendocrine (Merkel cell) carcinomas localized to the scalp. J Cutan Pathol; 2008 Jul;35(7):685-91
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous onset of multiple cutaneous neuroendocrine (Merkel cell) carcinomas localized to the scalp.
  • Merkel cell carcinoma (MCC) is a rare aggressive neoplasm that typically presents as a solitary nodule or plaque on sun-exposed skin of the elderly.
  • On low power, the tumor had the overall histological silhouette of a nodular basal cell carcinoma.
  • However, because of the lack of an epithelial connection and the cell's cytomorphological features, a MCC was considered and was subsequently confirmed using immunohistochemical stains.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Scalp / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331571.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


75. Velazquez EF, Melamed J, Barreto JE, Aguero F, Cubilla AL: Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases. Am J Surg Pathol; 2005 Sep;29(9):1152-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases.
  • A total of 400 cases of squamous cell carcinoma of the penis were reviewed from which 15 sarcomatoid carcinomas (4%) were identified.
  • Grossly, most tumors were large, polypoid, and ulcerated masses frequently affecting the glans (93%) and deeply invading corpora cavernosa (80%) and skin.
  • Four cases showed a minor mixed component of usual, papillary, verrucous, and basaloid carcinoma.
  • Intrapenile metastasis ("satellitosis") was present in 4 tumors.
  • One of the cases was multicentric with a separate independent focus of well-differentiated carcinoma with pseudohyperplastic features.
  • In conclusion, penile sarcomatoid carcinomas are unusual, large, and aggressive tumors usually associated with lymph node metastasis and poor outcome.
  • Diffuse immunoreactivity for p53, compared with a more basal and focal reactivity in differentiated squamous cell carcinoma, may be indicative of a late mutation in the natural progression of the disease.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Penile Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096403.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Ferreira M, Fujiwara H, Morita K, Watt FM: An activating beta1 integrin mutation increases the conversion of benign to malignant skin tumors. Cancer Res; 2009 Feb 15;69(4):1334-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An activating beta1 integrin mutation increases the conversion of benign to malignant skin tumors.
  • One of these, T188Ibeta1, was identified as a heterozygous mutation in a poorly differentiated squamous cell carcinoma (SCC) and shown to activate extracellular matrix adhesion and inhibit keratinocyte differentiation in vitro.
  • To study its contribution to tumor development, we overexpressed the mutant or wild-type (WT) human beta1 subunit in the basal layer of mouse epidermis using the keratin 14 promoter.
  • The transgenic integrins were expressed at the cell surface and were functional, with the T188Ibeta1 subunit promoting cell spreading to a greater extent than WTbeta1.
  • Epidermal proliferation and differentiation were unaffected and no expansion of the stem cell compartment was detected.
  • [MeSH-major] Antigens, CD29 / genetics. Mutation. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Adhesion. Cell Differentiation. Cell Division. Female. Flow Cytometry. Heterozygote Detection. Humans. In Situ Hybridization. Keratinocytes / cytology. Keratinocytes / physiology. Mice. Mice, Transgenic. Polymerase Chain Reaction. Polymorphism, Genetic. Skin / cytology


77. Brusevold IJ, Søland TM, Khuu C, Christoffersen T, Bryne M: Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model. Eur J Oral Sci; 2010 Aug;118(4):342-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model.
  • Met, the hepatocyte growth factor receptor, is important in transducing signals for tumour growth and metastasis.
  • The aim of this study was to examine the pattern of Met expression and its value as a prognostic factor in oral squamous cell carcinomas (OSCCs).
  • The material consisted of 53 OSCCs and five healthy controls from normal oral mucosa supplied with cell lines, 10 organotypic models supplied with oral cancer cells, and three organotypic models supplied with normal keratinocytes.
  • Met expression was scarce and limited to the basal layer in normal oral mucosa, but was more extensive in the tumours.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Mouth Neoplasms / pathology. Proto-Oncogene Proteins c-met / analysis
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Culture Techniques. Cell Line. Cells, Cultured. Coculture Techniques. Female. Fibroblasts / cytology. Gingiva / cytology. Humans. Keratinocytes / cytology. Keratins / analysis. Male. Middle Aged. Mouth Mucosa / cytology. Neoplasm Invasiveness. Prognosis. Skin Neoplasms / pathology. Tissue Scaffolds. Tongue Neoplasms / pathology. Up-Regulation


78. Eyden B, Moss J, Shore I, Banerjee SS: Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of lattice-deficient melanosomes. Ultrastruct Pathol; 2005 Jan-Feb;29(1):71-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of lattice-deficient melanosomes.
  • A case of metastatic malignant melanoma exhibiting small cell morphology is described.
  • The patient had had a previous primary nodular small cell melanoma.
  • Tumor cells were negative for S-100 protein and very focally positive for cytokeratin: these findings in combination with small cell morphology suggested the possibility of small cell carcinoma.
  • This is also the first case of small cell melanoma to be studied by electron microscopy.
  • [MeSH-major] Lymphatic Metastasis / pathology. Melanoma / pathology. Melanosomes / ultrastructure. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Microscopy, Electron, Transmission. Microscopy, Immunoelectron. Neoplasms, Multiple Primary / pathology. S100 Proteins / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15931781.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


79. Wimmer E, Kraehn-Senftleben G, Issing WJ: HER3 expression in cutaneous tumors. Anticancer Res; 2008 Mar-Apr;28(2A):973-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to elucidate the role of the receptor tyrosine kinase HER3, the expression characteristics in different tissues of cutaneous malignancies and in normal skin were compared.
  • MATERIALS AND METHODS: In this study HER3 expression was evaluated by RT-PCR analysis and immunohistochemistry from different tissue specimens of cutaneous tumors like nevi, primary malignant melanomas, basal cell carcinoma, squamous cell carcinoma and malignant melanoma metastases and normal skin samples and graded into weak, moderate and strong expression.
  • RESULTS: HER3 expression was found in 63% (10/16) of the basal cell carcinomas, in 4/5 of squamous cell carcinomas and in one Merkel cell carcinoma.
  • The majority of melanomas with a higher tumor thickness expressed HER3, and 85% of melanoma metastasis were HER3-positive.
  • [MeSH-major] Skin Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Humans. Immunohistochemistry. Melanoma / genetics. Melanoma / metabolism. Neoplasm Metastasis. Nevus. Receptor, ErbB-3 / genetics. Receptor, ErbB-3 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507044.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


80. Bongiovanni L, Colombi I, Fortunato C, Della Salda L: Survivin expression in canine epidermis and in canine and human cutaneous squamous cell carcinomas. Vet Dermatol; 2009 Oct;20(5-6):369-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in canine epidermis and in canine and human cutaneous squamous cell carcinomas.
  • Survivin, a member of the inhibitor of apoptosis protein (IAP) family, is ubiquitously expressed during tissue development, undetectable in most normal tissues, but re-expressed in most cancers, including skin malignancies.
  • Expression of survivin was evaluated retrospectively in 19 canine cutaneous squamous cell carcinomas (SCCs; one in situ; 16 well differentiated; one invasive, one lymph node metastasis) and 19 well differentiated SCCs from human beings.
  • Seven specimens of normal canine skin were included.
  • Scattered survivin positive nuclei were identified in the epidermal basal cell layer of normal canine skin.
  • Nuclear survivin expression was identified in 18 of 19 human and in all canine SCCs, mainly along the base of the tumour cell population.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cysteine Proteinase Inhibitors / metabolism. Gene Expression Regulation, Neoplastic / physiology. Microtubule-Associated Proteins / metabolism
  • [MeSH-minor] Animals. Dog Diseases / metabolism. Dogs. Humans. Inhibitor of Apoptosis Proteins. Mitosis. Retrospective Studies. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178473.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Cysteine Proteinase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


81. Guenova E, Lichte V, Hoetzenecker W, Woelbing F, Moehrle M, Roecken M, Schaller M: Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res; 2009 Aug;19(4):271-3
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunosuppressed patients are at increased risk of skin cancer.
  • The patient died of metastatic disease 3 months after the diagnosis was made.
  • Renal transplant recipients are at high risk of developing nonmelanocytic skin tumors when on immunosuppressive therapy with cyclosporine A.
  • Less common is the development of skin cancer during immunosuppression with azathioprine.
  • Our case illustrates the necessity of close dermatological surveillance of allograft recipients, to assure an early recognition of any malignant skin tumor and to reduce the risk of systemic metastatic disease.
  • [MeSH-major] Azathioprine / adverse effects. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Melanoma / etiology. Neoplasms, Multiple Primary / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / therapeutic use. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Therapy, Combination. Early Detection of Cancer. Humans. Lymphatic Metastasis. Male. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Nodular melanoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550360.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; MRK240IY2L / Azathioprine
  •  go-up   go-down


82. Gerstenblith MR, Goldstein AM, Tucker MA: Hereditary genodermatoses with cancer predisposition. Hematol Oncol Clin North Am; 2010 Oct;24(5):885-906
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article hereditary genodermatoses with cancer predisposition are reviewed, including nevoid basal cell carcinoma syndrome, neurofibromatosis types 1 and 2, tuberous sclerosis complex, xeroderma pigmentosum, and dyskeratosis congenita.
  • Early recognition and diagnosis allows for close follow-up and surveillance for associated malignancies.
  • [MeSH-major] Genetic Predisposition to Disease. Neoplastic Syndromes, Hereditary / genetics. Skin Diseases / genetics
  • [MeSH-minor] Animals. Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / therapy. Genetic Testing. Humans. Melanoma / genetics. Melanoma / therapy. Neurofibromatoses / genetics. Neurofibromatoses / therapy. Xeroderma Pigmentosum / genetics. Xeroderma Pigmentosum / therapy

  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Neurology. 2003 Jan 14;60(1):130-2 [12525736.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):507-16 [16421428.001]
  • [Cites] Curr Biol. 2003 Aug 5;13(15):1259-68 [12906785.001]
  • [Cites] Am J Cardiol. 2003 Aug 15;92(4):487-9 [12914889.001]
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] J Pediatr. 2003 Nov;143(5):620-4 [14615733.001]
  • [Cites] Annu Rev Genet. 2003;37:67-90 [14616056.001]
  • [Cites] Hum Genet. 2004 Feb;114(3):284-90 [14605872.001]
  • [Cites] Hum Mutat. 2004 Jun;23(6):630 [15146471.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):231-9 [15190457.001]
  • [Cites] Acta Neurol Taiwan. 2004 Mar;13(1):10-3 [15315295.001]
  • [Cites] BJU Int. 2004 Oct;94(6):853-7 [15476522.001]
  • [Cites] Am J Hum Genet. 1967 Jan;19(1):12-22 [4960000.001]
  • [Cites] Arch Dermatol. 1968 Jul;98(1):1-6 [4968649.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • [Cites] J Med Genet. 1978 Oct;15(5):352-6 [739524.001]
  • [Cites] Clin Exp Dermatol. 1985 Nov;10(6):562-5 [4092358.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):241-50 [3545087.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1383-92 [11390358.001]
  • [Cites] J Med Genet. 2001 May;38(5):347-9 [11403047.001]
  • [Cites] Neurology. 2001 Jun 12;56(11):1433-43 [11409413.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):765-73 [11500805.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):774-9 [11500806.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Respir Med. 2002 Jan;96(1):1-6 [11863203.001]
  • [Cites] Eur J Paediatr Neurol. 2002;6(1):15-23 [11993952.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):894-903 [12072543.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):306-10 [12068298.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5645-50 [12384518.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):585-91; discussion 602-4, 646-51 [12403557.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):653-4 [12424065.001]
  • [Cites] Ann Hum Genet. 2003 Jan;67(Pt 1):87-96 [12556239.001]
  • [Cites] J Urol. 2003 May;169(5):1635-42 [12686801.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1288-92 [12660952.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1348-9 [12711473.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1552-4 [12737880.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3053-62 [12789280.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):459-63 [12807969.001]
  • [Cites] Arch Dermatol. 2003 Jun;139(6):816-7 [12810525.001]
  • [Cites] Am J Hum Genet. 2003 Aug;73(2):301-13 [12844286.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Arch Dermatol. 1995 Aug;131(8):904-8 [7632061.001]
  • [Cites] Epilepsy Res. 2000 Feb;38(2-3):151-60 [10642043.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):1006-10 [10861313.001]
  • [Cites] Hum Mutat. 2000 Jul;16(1):89-90 [10874314.001]
  • [Cites] Dermatology. 2000;200(4):299-302 [10894959.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6 [10922411.001]
  • [Cites] J Child Neurol. 2000 Oct;15(10):652-9 [11063078.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):596-9 [7545742.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):90-2 [7550323.001]
  • [Cites] J Neurobiol. 1995 Aug;27(4):535-52 [7561832.001]
  • [Cites] J Neurosurg. 1996 Jan;84(1):20-8 [8613831.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):97-9 [8528263.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3245-51 [10506626.001]
  • [Cites] AMA Arch Derm Syphilol. 1951 Jan;63(1):73-84 [14789211.001]
  • [Cites] AMA Arch Derm. 1959 Jan;79(1):67-77; discussion 77-80 [13605278.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] J Child Neurol. 2004 Sep;19(9):650-7 [15563010.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] Hum Mutat. 2005 Apr;25(4):353-9 [15776433.001]
  • [Cites] Eur J Hum Genet. 2005 Jun;13(6):731-41 [15798777.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):10-8 [15880589.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2208-12 [16172233.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7168-77 [16192601.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2384-90 [16214921.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15 [16234564.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):660-6 [16397522.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] Ann Intern Med. 2006 Jun 6;144(11):842-9 [16754926.001]
  • [Cites] Am J Ophthalmol. 2006 Jun;141(6):1068-1077 [16765675.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):1047-51 [16861979.001]
  • [Cites] Am J Kidney Dis. 2006 Sep;48(3):e27-9 [16931204.001]
  • [Cites] Nat Genet. 1995 May;10(1):114-6 [7647780.001]
  • [Cites] J Dent Res. 2006 Sep;85(9):859-63 [16931872.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9818-28 [17047042.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] Ann Neurol. 2006 Nov;60(5):528-39 [17120248.001]
  • [Cites] Eur J Hum Genet. 2007 Feb;15(2):131-8 [16957683.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):99-106 [16905682.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):81-8 [17105749.001]
  • [Cites] Curr Opin Neurol. 2007 Apr;20(2):142-50 [17351483.001]
  • [Cites] Hum Mutat. 2007 May;28(5):495-505 [17279550.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1234-43 [17218939.001]
  • [Cites] Neuroscience. 2007 Apr 14;145(4):1388-96 [17276014.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):189-202 [17637444.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1439-47 [17468339.001]
  • [Cites] Nat Genet. 2007 Sep;39(9):1120-6 [17704776.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):832-6 [17848914.001]
  • [Cites] Chest. 2007 Sep;132(3):798-808 [17573495.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Feb;47(2):175-84 [18023021.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Cell. 1987 Jun 5;49(5):589-94 [2884037.001]
  • [Cites] Nature. 1987 Sep 17-23;329(6136):246-8 [2888021.001]
  • [Cites] N Engl J Med. 1988 Mar 17;318(11):684-8 [3125435.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1989 Dec;68(6):725-8 [2594320.001]
  • [Cites] Acta Neuropathol. 1989;79(2):137-43 [2596263.001]
  • [Cites] Arch Ophthalmol. 1990 Mar;108(3):328-9 [2310328.001]
  • [Cites] Neurofibromatosis. 1988;1(3):172-8 [3152465.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:125-7 [2039137.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:367-9 [2039161.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:8-16 [2039170.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):841-6 [1479598.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):847-52 [1479599.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Cancer Metastasis Rev. 1994 Mar;13(1):67-89 [8143346.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):15-21 [7987387.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):328-32 [7894481.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • [Cites] Br J Ophthalmol. 2001 Apr;85(4):420-3 [11264130.001]
  • [Cites] Cell. 2001 May 4;105(3):345-55 [11348591.001]
  • [Cites] Cell. 2001 May 4;105(3):357-68 [11348592.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4250-61 [19451225.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):920-5 [19578364.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):915-9 [19578365.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2009;10:45-61 [19405848.001]
  • [Cites] J Am Acad Dermatol. 2009 Oct;61(4):677.e1-14 [19751883.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7393-401 [19738042.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] Dermatol Surg. 2009 Oct;35(10):1576-81 [19681991.001]
  • [Cites] Lung Cancer. 2009 Nov;66(2):157-61 [19285750.001]
  • [Cites] Int J Cancer. 2010 Jan 15;126(2):563-71 [19634141.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • [Cites] Am J Hum Genet. 2007 Jan;80(1):140-51 [17160901.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Am J Hum Genet. 1996 Sep;59(3):529-39 [8751853.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4599-601 [8840969.001]
  • [Cites] Am J Hum Genet. 1997 Jan;60(1):21-6 [8981943.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1103-9 [9262247.001]
  • [Cites] Am J Hum Genet. 1997 Oct;61(4):843-51 [9382094.001]
  • [Cites] Am J Med Genet. 1997 Dec 12;73(2):197-204 [9409873.001]
  • [Cites] Arch Dermatol. 1997 Dec;133(12):1539-43 [9420538.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Hum Mol Genet. 1998 Feb;7(2):209-16 [9425228.001]
  • [Cites] Arch Neurol. 1998 Mar;55(3):379-84 [9520012.001]
  • [Cites] Hum Mol Genet. 1998 Jun;7(6):1053-7 [9580671.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] J Med Genet. 1998 Jun;35(6):450-5 [9643284.001]
  • [Cites] Hum Genet. 1998 May;102(5):598-601 [9654212.001]
  • [Cites] J Child Neurol. 1998 Dec;13(12):624-8 [9881533.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] J Child Neurol. 1999 Feb;14(2):71-4 [10073425.001]
  • [Cites] Am J Hum Genet. 1999 May;64(5):1305-15 [10205261.001]
  • [Cites] J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):877-90; quiz 891-2 [10365918.001]
  • [Cites] J Child Neurol. 1999 Jun;14(6):401-7 [10385849.001]
  • [Cites] Semin Ophthalmol. 2008 Jan-Feb;23(1):45-51 [18214791.001]
  • [Cites] P R Health Sci J. 2007 Dec;26(4):349-54 [18246963.001]
  • [Cites] Mech Ageing Dev. 2008 Jan-Feb;129(1-2):35-47 [18160098.001]
  • [Cites] BMC Dermatol. 2008;8:1 [18226258.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2753-60 [18366057.001]
  • [Cites] J Med Genet. 2008 May;45(5):284-9 [18178632.001]
  • [Cites] J Med Genet. 2008 May;45(5):303-8 [18285427.001]
  • [Cites] Ann Neurol. 2008 Apr;63(4):444-53 [18389497.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):838-40 [18488026.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):886-91 [18488027.001]
  • [Cites] Lancet. 2008 Aug 23;372(9639):657-68 [18722871.001]
  • [Cites] Mutat Res. 2008 Sep-Oct;659(3):284-92 [18598780.001]
  • [Cites] Eur J Med Genet. 2008 Sep-Oct;51(5):472-8 [18539553.001]
  • [Cites] Pediatrics. 2009 Jan;123(1):124-33 [19117870.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):221-7 [19151717.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(R1):R94-100 [19297407.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Apr;23(2):215-31 [19327580.001]
  • [Cites] Eur J Neurol. 2009 Jun;16(6):691-6 [19236458.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Jun;23(3):383-95, vii [19464592.001]
  • [Cites] Lancet. 2009 Jun 6;373(9679):1974-86 [19476995.001]
  • [Cites] Br J Haematol. 2009 Apr;145(2):164-72 [19208095.001]
  • [Cites] J Am Acad Dermatol. 2009 Jul;61(1):1-14; quiz 15-6 [19539839.001]
  • [Cites] Am J Med Genet A. 2009 Jul;149A(7):1539-43 [19533801.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20816579.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP004410-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS352798; NLM/ PMC3276063
  •  go-up   go-down


83. Moarbess G, El-Hajj H, Kfoury Y, El-Sabban ME, Lepelletier Y, Hermine O, Deleuze-Masquéfa C, Bonnet PA, Bazarbachi A: EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood; 2008 Apr 1;111(7):3770-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
  • Imiquimod is an immune response modifier currently used as a topical treatment of genital warts, basal cell carcinoma, cutaneous metastasis of malignant melanoma, and vascular tumors.
  • HTLV-I-associated adult T-cell leukemia (ATL) and HTLV-I-negative peripheral T-cell lymphomas are associated with poor prognosis.
  • Using potentially achievable concentrations of EAPB0203, we demonstrate inhibition of cell proliferation, G2/M cell- cycle arrest, and induction of apoptosis in HTLV-I-transformed and HTLV-I-negative malignant T cells and fresh ATL cells, whereas normal resting or activated T lymphocytes were resistant.
  • These results support a potential therapeutic role for EAPB0203 in ATL and HTLV-I-negative T-cell lymphomas, either as a systemic or topical therapy for skin lesions.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Caspases / metabolism. Cell Division / drug effects. G2 Phase / drug effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Quinoxalines / pharmacology. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218850.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / EAPB0203; 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 0 / Quinoxalines; 0 / Tumor Suppressor Protein p53; 0 / bcl-X Protein; 9007-43-6 / Cytochromes c; 99011-02-6 / imiquimod; EC 3.4.22.- / Caspases
  •  go-up   go-down


84. Wolf IH, Kodama K, Cerroni L, Kerl H: Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol; 2007 Jun;29(3):237-41
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical imiquimod (IQ) is an effective treatment for genital warts and various malignant tumors of the skin.
  • We investigated the composition of the inflammatory cell infiltrate before, during, and after the treatment of 10 superficial cutaneous malignancies (melanoma in situ (n = 4), melanoma metastasis (n = 1), squamous cell carcinoma in situ (n = 4), and basal cell carcinoma (n = 1) with 5% IQ cream.
  • These findings further support previous investigations that the antitumor effects of IQ result from an enhanced cytotoxic T-cell mediated immune response and from the recruitment of plasmacytoid dendritic cells to the skin.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Inflammation / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Bowen's Disease / chemistry. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma in Situ / chemistry. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Female. Humans. Hutchinson's Melanotic Freckle / chemistry. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / pathology. Keratosis / drug therapy. Keratosis / metabolism. Keratosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519620.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Biomarkers, Tumor; 99011-02-6 / imiquimod
  •  go-up   go-down


85. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST: Mast cells and cutaneous malignancies. Mod Pathol; 2006 Jan;19(1):149-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers.
  • These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma.
  • Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix.
  • Mast cell proteases reorganize the stroma to facilitate endothelial cell migration.
  • As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.
  • [MeSH-major] Mast Cells / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258517.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 71
  •  go-up   go-down


86. Fukumaru K, Yoshii N, Kanzaki T, Kanekura T: Immunohistochemical comparison of beta-catenin expression by human normal epidermis and epidermal tumors. J Dermatol; 2007 Nov;34(11):746-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • beta-Catenin, a cytoplasmic protein that binds directly to the intracellular domain of cadherin, controls various functions such as cell adhesion.
  • In many human carcinomas, E-cadherin-mediated cell-cell adhesion is lost or disturbed and related to metastasis.
  • Using immunohistochemical methods, we compared the expression of beta-catenin in their normal epidermal keratinocytes, and in samples from 61 benign (seborrheic keratosis, n = 33; verruca vulgaris, n = 14; keratoacanthoma, n = 14), and 79 malignant (Bowen's disease, n = 18; basal cell carcinoma, n = 33; squamous cell carcinoma, n = 28) epidermal tumors. beta-Catenin was found to be expressed in the cell membrane of normal keratinocytes.
  • Compared to other cell components of the normal epidermis, basal cells showed the strongest beta-catenin expression in all 140 patients.
  • While absent in three of 61 benign tumors, compared to normal basal cells, the expression of beta-catenin in the other 58 tumors was not significantly different; it was reduced in 71 of 79 malignant tumors (P < 0.0001).
  • In Bowen's disease, the expression of beta-catenin on the tumor cell membrane was reduced, however, strong expression was seen in the nuclei and cytoplasm.
  • [MeSH-major] Epidermis / metabolism. Keratinocytes / metabolism. Skin Diseases / metabolism. Skin Neoplasms / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Bowen's Disease / metabolism. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Humans. Immunohistochemistry. Keratoacanthoma / metabolism. Keratosis, Seborrheic / metabolism. Warts / metabolism. Warts / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17973813.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / beta Catenin
  •  go-up   go-down


87. Chiu CS, Lin CY, Kuo TT, Kuan YZ, Chen MJ, Ho HC, Yang LC, Chen CH, Shih IH, Hong HS, Chuang YH: Malignant cutaneous tumors of the scalp: a study of demographic characteristics and histologic distributions of 398 Taiwanese patients. J Am Acad Dermatol; 2007 Mar;56(3):448-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Age at diagnosis, sex, and histologic types were analyzed.
  • Age at diagnosis ranged from 3 to 103 years.
  • Basal (41.2%) and squamous (16.6%) cell carcinomas were the most common histologic types.
  • LIMITATIONS: In our series, the case number of metastatic scalp malignancies was underestimated because not all patients with metastatic scalp tumors received a scalp skin biopsy.
  • CONCLUSION: Because a wide spectrum of primary and metastatic malignancies can occur on the scalp, scalp inspection should be included in general screening for either skin or internal cancers.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Head and Neck Neoplasms / epidemiology. Scalp. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Dermatofibrosarcoma / epidemiology. Female. Hemangiosarcoma / epidemiology. Humans. Incidence. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sex Distribution. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141358.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Asuquo ME, Ngim O, Ugare G, Omotoso J, Ebughe G: Major dermatologic malignancies encountered in a teaching hospital surgical department in South Nigeria. Am J Clin Dermatol; 2008;9(6):383-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, dark-skinned individuals of African descent are said to be far less likely than fair-skinned individuals to develop skin cancer.
  • Significant differences in the pattern of skin malignancy have also been observed in different regions of Africa.
  • Squamous cell carcinoma (SCC) was the most common (n = 23; 37%), followed by Kaposi sarcoma (KS) [n = 17; 27%].
  • Other malignancies included basal cell carcinoma (BCC), melanoma, and dermatofibrosarcoma protuberans (DFSP) [n = 5; 8% each].
  • [MeSH-major] Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Africa / epidemiology. African Continental Ancestry Group. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Hospitals, Teaching / statistics & numerical data. Humans. Male. Melanoma / pathology. Melanoma / surgery. Neoplasm Metastasis. Nigeria. Retrospective Studies. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18973404.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


89. Combemale P, Bousquet M, Kanitakis J, Bernard P, Angiodermatology Group, French Society of Dermatology: Malignant transformation of leg ulcers: a retrospective study of 85 cases. J Eur Acad Dermatol Venereol; 2007 Aug;21(7):935-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For squamous cell carcinomas (SCC), the duration of the ulcer had to be longer than 3 years.
  • For basal cell carcinomas (BCC), a negative previous biopsy of the ulcer was considered.
  • The high death rate, especially in metastatic cases, is at least partly due to delay in diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Leg Ulcer / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amputation. Cell Transformation, Neoplastic. Female. France / epidemiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659003.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


90. Filippou DK, Filippou G, Trigka A, Condilis N, Kiparidou E, Skandalakis P, Rizos S: Malignant proliferating trichilemmal tumour of the scalp. Report of a case and a short review of the literature. Ann Ital Chir; 2006 Mar-Apr;77(2):179-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant proliferating trichilemmal tumour is a rare skin tumour that originates from the root sheath of the hair and usually arises in the sun-exposed areas of elderly women.
  • It mimicks poorly differential squamous cell carcinoma ant its biological behaviour is unpredictable, because rarely can produce distant metastases.
  • In the reported case, although the high risk of distant metastasis, two years after the tumour resection the patient is free of disease, It is also reported a short review of the literature.
  • The appropriate treatment includes wide resection and dose postoperative follow-up of the patient to facilitate the early diagnosis of distant metastases.
  • [MeSH-major] Neoplasms, Basal Cell / surgery. Scalp. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147095.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


91. Kazakov DV, Vittay G, Michal M, Calonje E: High-grade trichoblastic carcinosarcoma. Am J Dermatopathol; 2008 Feb;30(1):62-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was excised, and the patient had no evidence of recurrence or metastasis 6 years after surgery.
  • We view the present case and that previously reported in 2004 as authentic carcinosarcomas, and not as metaplastic (sarcomatoid) basal cell carcinomas.
  • [MeSH-major] Carcinosarcoma / pathology. Hair Diseases / pathology. Hair Follicle / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Ear / pathology. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212548.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Osborne RF, Shaw T, Zandifar H, Kraus D: Elective parotidectomy in the management of advanced auricular malignancies. Laryngoscope; 2008 Dec;118(12):2139-45
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with a clinical history of advanced nonmelanoma auricular carcinoma undergoing elective parotidectomy and/or neck dissection with clinically and radiographically N0 nodal disease were evaluated for the presence of occult parotid metastasis.
  • All patients underwent parotidectomy in conjunction with a total auriculectomy for surgical extirpation of their primary auricular carcinoma.
  • RESULTS: Pathological examination showed no histological evidence of occult parotid metastasis in all 19 patients who underwent elective parotidectomy in the presence of clinically and radiographically N0 nodal disease of the parotid or cervical regions.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Ear Neoplasms / surgery. Ear, External. Elective Surgical Procedures. Parotid Gland / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029866.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Rünger TM: Cathepsin K in melanoma invasion. J Invest Dermatol; 2008 Sep;128(9):2281-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, catK expression has been reported in skin and lung fibroblasts, which suggests a role in maintaining homeostasis of the extracellular matrix outside of bone.
  • Matrix degradation is a pivotal step in tumor invasion and metastasis.
  • Inhibition of catK greatly reduced melanoma cell invasion through Matrigel basement membrane matrix and increased detection of internalized collagen.
  • We suggest that catK may play an important role in melanoma invasion and metastasis by mediating intracellular degradation of matrix proteins after phagocytosis.
  • [MeSH-major] Cathepsins / antagonists & inhibitors. Cathepsins / metabolism. Melanoma / metabolism. Neoplasm Invasiveness. Skin Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cathepsin K. Cells, Cultured. Collagen Type IV / metabolism. Extracellular Matrix / metabolism. Humans. Male. Melanocytes / cytology. Melanocytes / metabolism. Melanocytes / pathology. Nevus, Pigmented / metabolism. Nevus, Pigmented / pathology. Phagocytosis. RANK Ligand / metabolism. Receptor Activator of Nuclear Factor-kappa B / metabolism. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18368130.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / RANK Ligand; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / TNFRSF11A protein, human; 0 / TNFSF11 protein, human; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K
  •  go-up   go-down


94. Cózar MP, Ferrer-Rebolleda J, Redal MC, Moreno A, Tortajada L, Casáns I, Romero C: [Sentinel lymph node biopsy in cutaneous non-melanoma malignancies]. Rev Esp Med Nucl; 2006 Jan-Feb;25(1):10-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SLN position was marked on the skin and after a correct localization in the surgical field with a gamma probe the SLN was obtained.
  • [MeSH-major] Lymphatic Metastasis / diagnosis. Sentinel Lymph Node Biopsy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / diagnosis. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / radionuclide imaging. Carcinoma, Basal Cell / secondary. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / radionuclide imaging. Carcinoma, Merkel Cell / secondary. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Child. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / radionuclide imaging. Dermatofibrosarcoma / secondary. False Negative Reactions. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Technetium Tc 99m Aggregated Albumin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540005.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


95. Tran M, Rousselle P, Nokelainen P, Tallapragada S, Nguyen NT, Fincher EF, Marinkovich MP: Targeting a tumor-specific laminin domain critical for human carcinogenesis. Cancer Res; 2008 Apr 15;68(8):2885-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laminin-332 is critical for squamous cell carcinoma (SCC) tumorigenesis, but targeting it for cancer therapy has been unachievable due to key role of laminin-332 in promoting tissue integrity.
  • Primary human keratinocytes lacking G45 (DeltaG45) showed alterations of basal receptor organization, impaired matrix deposition, and increased migration.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Adhesion Molecules / metabolism. Cell Transformation, Neoplastic
  • [MeSH-minor] Epidermolysis Bullosa / genetics. Epidermolysis Bullosa / pathology. Humans. Keratinocytes / physiology. Neoplasm Invasiveness. Neoplasm Metastasis. Skin Physiological Phenomena

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413757.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR44012; United States / NIAMS NIH HHS / AR / AR47223
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / kalinin
  •  go-up   go-down


96. Bagot M: [What's new in oncodermatology?]. Ann Dermatol Venereol; 2009 Dec;136 Suppl 7:S436-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Merkel cell polyoma virus seems rather ubiquitous, since it has been evidenced, without clonal integration, in several other types of cutaneous tumors, and even in healthy skin, with an increased frequency in photo-exposed skin and in immunodepressed patients.
  • In contrast, the effect of interferon on relapse free survival, distant metastasis free survival and overall survival seems better in the subgroup of melanoma with primary ulceration.
  • [MeSH-major] Carcinoma. Dermatology / trends. Lymphoma. Melanoma. Skin Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Basal Cell. Carcinoma, Merkel Cell. Evidence-Based Medicine. France / epidemiology. Glucocorticoids / adverse effects. Humans. Immunologic Factors / administration & dosage. Incidence. Interferon-alpha / administration & dosage. Lymphoma, B-Cell. Lymphoma, T-Cell, Cutaneous. Pesticides / adverse effects. Prognosis. Proto-Oncogene Proteins B-raf / antagonists & inhibitors. Risk Factors. SEER Program. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20110059.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Pesticides; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 35
  •  go-up   go-down


97. Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, Muccio DD, Grubbs CJ, Ruppert JM, Lobo-Ruppert SM: Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid. Cancer Biol Ther; 2009 Feb;8(3):289-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the skin KLF4 is co-expressed with the nuclear receptors RARgamma and RXRalpha, and formation of the skin permeability barrier is a shared function of these three proteins.
  • We utilized a KLF4-transgenic mouse model of skin cancer in combination with cultured epithelial cells to examine functional interactions between KLF4 and retinoic acid receptors.
  • We tested retinoids in epithelial cell transformation assays, including an RAR-selective agonist (all-trans RA), an RXR-selective agonist (9-cis UAB30, rexinoid), and a pan agonist (9-cis RA).
  • Similarly as shown for other mouse models of skin cancer, rexinoid prevented skin tumor initiation resulting from induction of KLF4 in basal keratinocytes.
  • Rexinoid permitted KLF4 expression and KLF4-induced cell cycling, but attenuated the KLF4-induced misexpression of cytokeratin 1 in basal cells.
  • Neoplastic lesions including hyperplasia, dysplasia and squamous cell carcinoma-like lesions were prevented for up to 30 days.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1232-9 [16344269.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1283-98 [16564017.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):793-810 [17906642.001]
  • [Cites] J Biochem. 2008 Sep;144(3):313-21 [18511453.001]
  • [Cites] Nat Genet. 2008 Sep;40(9):1130-5 [19165927.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):633-6 [11034212.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]
  • [Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3402-13 [12093741.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):208-13 [12539049.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8771-9 [12496248.001]
  • [Cites] J Med Chem. 2003 Aug 14;46(17):3766-9 [12904083.001]
  • [Cites] Cancer Lett. 2003 Nov 10;201(1):17-24 [14580682.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):341-51 [15093541.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1747-55 [15073042.001]
  • [Cites] Anal Biochem. 1987 Oct;166(1):49-54 [3674416.001]
  • [Cites] Nucleic Acids Res. 1990 Jun 25;18(12):3587-96 [2194165.001]
  • [Cites] Mol Cell Biol. 1991 Mar;11(3):1724-8 [1825351.001]
  • [Cites] J Cell Biol. 1994 Nov;127(4):1085-96 [7525602.001]
  • [Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cell. 1995 Dec 15;83(6):841-50 [8521508.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]
  • [Cites] FASEB J. 1996 Jul;10(9):940-54 [8801176.001]
  • [Cites] FASEB J. 1996 Jul;10(9):1002-13 [8801161.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31384-90 [8940147.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6265-73 [9343387.001]
  • [Cites] Cancer Metastasis Rev. 1997 Sep-Dec;16(3-4):349-56 [9433644.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):29-35 [9456240.001]
  • [Cites] J Med Chem. 1998 May 7;41(10):1679-87 [9572893.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3149-55 [9784489.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]
  • [Cites] Mol Cell Biol. 1999 Aug;19(8):5696-706 [10409758.001]
  • [Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1491-500 [15674344.001]
  • [Cites] Eur J Cancer Prev. 2007 Jun;16(3):203-15 [17415091.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1250-60 [17301838.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):357-69 [17446857.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4489-98 [17297467.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10394-400 [16288030.001]
  • [Cites] Nat Cell Biol. 2005 Nov;7(11):1074-82 [16244670.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Cancer Biol Ther. 2005 Dec;4(12):1401-8 [16357510.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1525-38 [16751185.001]
  • (PMID = 19197145.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089019-070009; United States / NCI NIH HHS / CA / CA127405-02; United States / NCI NIH HHS / CA / R01 CA127405-01; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / CA094030-05; United States / NCI NIH HHS / CA / CA089019-06A20009; United States / NCI NIH HHS / CA / R01 CA094030-05; United States / NCI NIH HHS / CA / R01 CA094030; United States / NCI NIH HHS / CA / P50 CA089019-070009; United States / NIAMS NIH HHS / AR / AR050948; United States / NCI NIH HHS / CA / P50 CA089019-06A20009; United States / NCI NIH HHS / CA / P50 CA89019; United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / R01 CA127405-02; United States / NCI NIH HHS / CA / R01 CA127405; United States / NCI NIH HHS / CA / CA127405-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fatty Acids, Unsaturated; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Naphthalenes; 0 / Receptors, Retinoic Acid; 0 / Recombinant Fusion Proteins; 0 / Retinoid X Receptor alpha; 0 / UAB 30; 0 / retinoic acid receptor gamma; 5688UTC01R / Tretinoin; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ NIHMS94168; NLM/ PMC2776760
  •  go-up   go-down


98. Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF: Gene expression profiling of cutaneous wound healing. J Transl Med; 2007;5:11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: This study was part of a placebo-controlled double-blind clinical trial in which basal cell carcinomas were treated topically with an immunomodifier--toll-like receptor 7 agonist: imiquimod.
  • The fourteen patients with basal cell carcinoma in the placebo arm of the trial received placebo treatment consisting solely of vehicle cream.
  • A skin punch biopsy was obtained immediately before treatment and at the end of the placebo treatment (after 2, 4 or 8 days).
  • [MeSH-major] Gene Expression Profiling. Skin / metabolism. Skin / pathology. Wound Healing / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thromb Haemost. 2006 May;4(5):932-9 [16689737.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):755-9 [10629031.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):315-22 [16967326.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7303-11 [17082649.001]
  • [Cites] Wound Repair Regen. 2006 Mar-Apr;14(2):129-37 [16630101.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):651-8 [16325811.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):6020-9 [16365041.001]
  • [Cites] Autoimmun Rev. 2006 Feb;5(2):129-31 [16431343.001]
  • [Cites] J Thromb Haemost. 2006 Jan;4(1):19-25 [16129024.001]
  • [Cites] Genome Biol. 2005;6(2):R15 [15693944.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] Wound Repair Regen. 2004 Jul-Aug;12(4):461-70 [15260812.001]
  • [Cites] Keio J Med. 2004 Jun;53(2):74-7 [15247510.001]
  • [Cites] FASEB J. 2004 May;18(7):816-27 [15117886.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:283-9 [14766366.001]
  • [Cites] Adv Skin Wound Care. 2004 Jan-Feb;17(1):24-35 [14752324.001]
  • [Cites] J Mol Med (Berl). 2003 Oct;81(10):600-12 [12928786.001]
  • [Cites] Nat Med. 2003 Feb;9(2):225-9 [12524533.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Wound Repair Regen. 2002 May-Jun;10(3):130-32 [12164164.001]
  • [Cites] Curr Pharm Des. 2001 Jul;7(11):1083-103 [11472255.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Nat Biotechnol. 2000 Apr;18(4):457-9 [10748532.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Genome Biol. 2007;8(1):R8 [17222352.001]
  • (PMID = 17313672.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Biomarkers; 0 / Placebos; 99011-02-6 / imiquimod
  • [Other-IDs] NLM/ PMC1804259
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


99. Belmahi A, Oufkir AA: [Local flaps in the treatment of full thickness scalp defects secondary to advanced cutaneous malignancy. About 21 clinical cases]. Ann Chir Plast Esthet; 2007 Dec;52(6):569-76
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From May 2001 to July 2006, 21 patients aged between 52 and 78 years old, suffering from advanced basal and squamous cell carcinomas with invasion of the calvarium in all cases, the dura in 1 case and the cerebral tissue in 2 cases have benefited from an excision of the scalp and calvarium with a margin between 1 and 3 cm.
  • The other patients are still alive without any recurrence or metastasis with a mean follow-up of 36 months.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Postoperative Complications / surgery. Reconstructive Surgical Procedures / methods. Scalp / surgery. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382442.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


100. van der Velden HM, van Rossum MM, Blokx WA, Boezeman JB, Gerritsen MJ: Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients. Dermatol Res Pract; 2009;2009:479183

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We collected data on patients who visited the Department of Dermatology at the Radboud University Nijmegen Medical Centre and were newly diagnosed with cutaneous melanoma or metastasis of melanoma with unknown primary localization between 2002 and 2006.
  • A total of 194 cases were included; eleven patients developed a subsequent melanoma, 24 had at least one basal cell carcinoma, three had at least one squamous cell carcinoma, and 21 patients had a second non-cutaneous primary malignancy.
  • As nonmelanoma skin cancer is the most frequent second malignancy, our results subscribe to the necessity of follow-up by a dermatologist.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1200-6 [14674897.001]
  • [Cites] Arch Dermatol. 2003 Dec;139(12):1620-4; discussion 1624 [14676081.001]
  • [Cites] Eur J Cancer Prev. 2004 Feb;13(1):33-7 [15075786.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):634-8 [15373766.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):616-24 [15630700.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):481-8 [15787817.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2669-75 [15837981.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2040-59 [16125929.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):743-51 [16495934.001]
  • [Cites] Arch Dermatol. 2006 Apr;142(4):433-8 [16618861.001]
  • [Cites] Ned Tijdschr Geneeskd. 2006 Nov 11;150(45):2490-6 [17137098.001]
  • [Cites] J Am Acad Dermatol. 2007 May;56(5):768-73 [17337091.001]
  • [Cites] Mayo Clin Proc. 2007 Mar;82(3):364-80 [17352373.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1747-54 [1516030.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1911-6 [1525766.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):660-5 [2065289.001]
  • [Cites] Br J Cancer. 1990 Jun;61(6):932-6 [2372499.001]
  • [Cites] Ann Surg. 1970 Nov;172(5):902-8 [5477666.001]
  • [Cites] Cancer Res. 1969 Mar;29(3):705-27 [5773814.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):970-4 [7666916.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):975-7 [7666917.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):350S-355S [8440923.001]
  • [Cites] Br J Cancer. 1996 Jan;73(2):255-9 [8546916.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1571-8 [8635060.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2325-31 [8635103.001]
  • [Cites] Ned Tijdschr Geneeskd. 1996 Jun 29;140(26):1347-50 [8710022.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39 [9326912.001]
  • [Cites] Melanoma Res. 1998 Aug;8(4):361-6 [9764812.001]
  • [Cites] Melanoma Res. 1998 Dec;8(6):573-83 [9918420.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):705-11 [10560858.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2014-20 [10570426.001]
  • [Cites] Dermatol Surg. 2000 Jun;26(6):547-50 [10848935.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6 [10922411.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1269-78 [11002222.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):678-83 [11333289.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Nov;14(6):479-83 [11444270.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):371-3 [11535880.001]
  • [Cites] Eur J Epidemiol. 2001;17(2):169-74 [11599692.001]
  • [Cites] Eur J Cancer Prev. 2001 Oct;10(5):407-15 [11711755.001]
  • [Cites] Br J Dermatol. 2001 Dec;145(6):981-5 [11899153.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Dermatology. 2003;206(2):76-7 [12592070.001]
  • [Cites] J Invest Dermatol. 2003 Jun;120(6):1087-93 [12787139.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3598-605 [14506146.001]
  • (PMID = 20585479.001).
  • [ISSN] 1687-6113
  • [Journal-full-title] Dermatology research and practice
  • [ISO-abbreviation] Dermatol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2879611
  •  go-up   go-down






Advertisement